{
    "0LW.F": {
        "short_name": "NEOVACS NOM.  EO-,05",
        "long_name": "Neovacs S.A.",
        "summary": "Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "France",
        "city": "Paris"
    },
    "1DJ.F": {
        "short_name": "BASTIDE,L.CONF.M.INH.",
        "long_name": "Bastide Le Confort M\u00e9dical SA",
        "summary": "Bastide Le Confort M\u00c3\u00a9dical SA engages in the sale and rental of medical equipment in France. The company offers comfort and health products, such as lift chairs, bathroom and well-being products, pillows and cushions, seats, phones keys, measuring devices, technical aids, fitness products, blood pressure monitors, and pillboxes ; and incontinence products, including absorbent and support briefs, anatomical protections, protections for men and women, disposable mattress pads, PVC panties, and hygiene and body care products. It also provides medical materials comprising home support products wheel chairs, electric scooters, walkers, bed tables and rails, and transfer aids, air mattress, sick lifts, and standers; and medical equipment consisting of consumables, care and dressings, hygiene and disinfection products, outfits and briefcases, and other medical equipment, as well as home support services for elderly, senior, or disabled. It offers its products through approximately 130 stores, as well as through an online store. The company was founded in 1977 and is headquartered in Caissargues, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Distribution",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "France",
        "city": "Caissargues"
    },
    "1F6.F": {
        "short_name": "FERMENTALG  EO -,04",
        "long_name": "Fermentalg Soci\u00e9t\u00e9 Anonyme",
        "summary": "Fermentalg Soci\u00c3\u00a9t\u00c3\u00a9 Anonyme develops, produces, and sells active ingredients extracted from microalgae for the food, health, and nutrition sectors in France and internationally. It offers DHA ORIGINS, a plant based DHA oil; PROTEALG, a vegetable protein; BLUE ORIGIN, a natural color substitutes for human health and nutrition; and Carbon sinks to capture CO2 in urban and industrial environments. The company was founded in 2009 and is based in Libourne, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "France",
        "city": "Libourne"
    },
    "1MK.F": {
        "short_name": "MAUNA KEA TECHNOL.EO -,04",
        "long_name": "Mauna Kea Technologies SA",
        "summary": "Mauna Kea Technologies SA develops and markets medical devices for the diagnosis and treatment of cancers and other diseases in Europe, the Middle East, Africa, the United States, Latin America, China, and Japan. Its flagship product is Cellvizio, a multidisciplinary probe and needle-based confocal laser endomicroscopy platform, which provides physicians and researchers with images of tissues at the cellular level. The company was founded in 2000 and is headquartered in Paris, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "France",
        "city": "Paris"
    },
    "2E4.F": {
        "short_name": "ERYTECH PHARMA SA  EO-,10",
        "long_name": "ERYTECH Pharma S.A.",
        "summary": "ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases. The company's lead product candidate is eryaspase, which is in Phase III clinical development for the treatment of second-line pancreatic cancer and in Phase II stage for the treatment of triple-negative breast cancer. It also engages in developing erymethionase, a preclinical product candidate that consists of methionine-gamma-lyase encapsulated in red blood cells to target methionine-dependent cancers. ERYTECH Pharma S.A. has research collaborations with the Fox Chase Cancer Center to advance the preclinical development of erymethionase for the treatment of homocystinuria; and Queen's University of Canada to advance the preclinical development of eryminase for the treatment of arginase-1-deficiency. The company was founded in 2004 and is headquartered in Lyon, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "France",
        "city": "Lyon"
    },
    "2E4A.F": {
        "short_name": "ERYTECH PHARMA SP.ADR-,10",
        "long_name": "ERYTECH Pharma S.A.",
        "summary": "ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases. The company's lead product candidate is eryaspase, which is in Phase III clinical development for the treatment of second-line pancreatic cancer and in Phase II stage for the treatment of triple-negative breast cancer. It also engages in developing erymethionase, a preclinical product candidate that consists of methionine-gamma-lyase encapsulated in red blood cells to target methionine-dependent cancers. ERYTECH Pharma S.A. has research collaborations with the Fox Chase Cancer Center to advance the preclinical development of erymethionase for the treatment of homocystinuria; and Queen's University of Canada to advance the preclinical development of eryminase for the treatment of arginase-1-deficiency. The company was founded in 2004 and is headquartered in Lyon, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "France",
        "city": "Lyon"
    },
    "2N3.F": {
        "short_name": "LNA SANTE SA  EO 2",
        "long_name": "LNA Sant\u00e9 SA",
        "summary": "LNA Sant\u00c3\u00a9 SA operates and manages full-care facilities for the dependent elderly persons under the LNA Sant\u00c3\u00a9 brand in France and Belgium. The company operates nursing homes, follow-up care and rehabilitation facilities, home hospitalization structures, health centers, and psychiatric clinics. It serves patients with complex, acute, or chronic pathologies comprising neurological, respiratory, cardiovascular, psychiatric, etc. The company operates 11 clinics; 1 psychiatric clinic; and 7 home care facilities. LNA Sant\u00c3\u00a9 SA was founded in 1990 and is based in Vertou, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "France",
        "city": "Vertou"
    },
    "2X1.F": {
        "short_name": "ABIVAX SA  EO -,01",
        "long_name": "ABIVAX Soci\u00e9t\u00e9 Anonyme",
        "summary": "ABIVAX Soci\u00c3\u00a9t\u00c3\u00a9 Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the development of ABX 544, a drug candidate for the treatment of Ebola based on polyclonal antibodies; and research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Soci\u00c3\u00a9t\u00c3\u00a9 Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was founded in 2013 and is headquartered in Paris, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "France",
        "city": "Paris"
    },
    "37S.SG": {
        "short_name": "Spineway Actions au Port. EO -,",
        "long_name": "Spineway Soci\u00e9t\u00e9 Anonyme",
        "summary": "Spineway Soci\u00c3\u00a9t\u00c3\u00a9 Anonyme engages in the design, manufacture, and marketing of implant lines and surgical equipment for treating spinal column pathologies. The company offers Ayers Rock, an anterior cervical interbody fusion cage; Blue Mountain, an anterior cervical interbody fusion plate; Mont Blanc, a posterior thoracolumbar system; Mont Blanc Baby, a posterior thoracolumbar pediatric system; Mont Blanc 3D+, a posterior for direct correction; Kili, an anterior lumbar interbody fusion cage; Twin peaks PLIF bullet shaped posterior lumbar interbody fusion cages; Twin peaks OLIF oblique lumbar interbody fusion cages; Twin peaks TLIF transforaminal lumbar interbody fusion cages; and Mont Blanc MIS, a mini-invasive thoracolumbar system. It also provides Sonora and Neve bone substitutes; Rift lumbar and Rift cervical instrumentation for spinal surgery; and Rift invasive solution. In addition, the company exports its products to approximately 50 countries through distributors. Spineway Soci\u00c3\u00a9t\u00c3\u00a9 Anonyme was founded in 2005 and is headquartered in Ecully, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "STU",
        "market": "dr_market",
        "country": "France",
        "city": "Ecully"
    },
    "3MM.F": {
        "short_name": "ADVICENNE (PROM.) EO-,20",
        "long_name": "Advicenne S.A.",
        "summary": "Advicenne S.A., a late-stage biopharmaceutical company, develops pediatric therapeutics for the treatment of orphan renal diseases and niche neurology indications. Its lead product is ADV7103, which has completed Phase III study for the treatment of distal renal tubular acidosis in children and adults, as well as in Phase III clinical studies for the treatment of cystinuria, an inherited renal tubulopathy. The company also provides ADV6209, an oral liquid solution for children to reduce anxiety and to improve their immobility; Likozam to treat partial and generalized chronic refractory epilepsy in children and adults; and Levidcen, a granulated formulation of levetiracetam for the treatment of epilepsy in children and adults. Advicenne S.A. was founded in 2007 and is headquartered in Paris, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "France",
        "city": "Paris"
    },
    "4G8.F": {
        "short_name": "GUERBET SA INH.  EO 1",
        "long_name": "Guerbet SA",
        "summary": "Guerbet SA engages in the research, development, production, and sale of contrast media products, delivery systems, medical devices, and related solutions worldwide. Its products for the CT and Cath Lab examinations include Optiray, a low osmolar contrast medium; Xenetix, a low-osmolar iodinated agent; Telebrix, a high osmolar contrast medium; Conray and MD high osmolar contrast medium products; Hexabrix, an ionic low osmolar contrast medium agent; and Micropaque/ Microtrast, a diagnostic imaging interconnected solution. The company's products for the magnetic resonance imaging examinations comprise Dotarem, a non-specific gadolinium-based contrast medium; Artirem products; and Optimark, a contrast medium. In addition, it provides products for interventional imaging, including Lipiodol ethyl esters of iodinated fatty acids of poppy seed oil; Vectorio, a classic transarterial chemoembolization mixing and injection system; Patent Blue V, an injectable medium; and SeQure and DraKon, a microcatheters. Further, the company offers delivery systems and services comprising injectors; consumables for various types of injectors; Contrast&Care, a patient data management software; Dose&Care, an operational solution for monitoring patient exposure to ionizing radiation; and Hydra Vision, a digital imaging system for urological, gastroenterological, gynecological treatment, and planning and diagnostic procedures. The company distributes its products directly, as well as through distributors and license-holders primarily to hospitals, clinics, radiology centers, purchasing pools, and wholesalers. Guerbet SA was founded in 1926 and is headquartered in Villepinte, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "France",
        "city": "Villepinte"
    },
    "56S1.F": {
        "short_name": "SARTOR.STED.B. EO-,20",
        "long_name": "Sartorius Stedim Biotech S.A.",
        "summary": "Sartorius Stedim Biotech S.A. produces and sells instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; and a range of products for separation, purification, and concentration processes, as well as systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, filtration, purification, fluid management services, and membrane chromatography services. In addition, the company offers data analytics software for modeling and optimizing processed of biopharmaceutical development and production. It serves manufacturers of pharmaceuticals, foods, and chemicals, as well as research and development laboratories. The company was founded in 1870 and is headquartered in Aubagne, France. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "France",
        "city": "Aubagne"
    },
    "5D8.F": {
        "short_name": "DEINOVE  EO-,40",
        "long_name": "Deinove SA",
        "summary": "DEINOVE SA, a biotech company, discovers, develops, and produces compounds originating from microbials for the health, nutrition, and cosmetics industries worldwide. The company's antibiotic candidates include DNV3837, an antibiotic, which is in the Phase II clinical trial for the treatment of Clostridioides difficile infections. It also offers PHYT-N-Resist, an anti-aging active ingredient for cosmetics; Luminity, a carotenoid-based ingredient to absorb blue light and exceptional antioxidant properties; HEBELYS, a natural active ingredient produced by fermentation of Sphingomonas; and BIOME Ol\u00c3\u00a9oactif, which acts as a post-biotic extract with a prebiotic effect to balance the skin microbiota. In addition, the company develops a process for producing natural ingredients for animal feed. DEINOVE SA has partnership agreements primarily with bioM\u00c3\u00a9rieux, Naicons, Medpace, Institut Pasteur, Hallstar Group, Sharon Laboratories, Ol\u00c3\u00a9os-Hallstar, Greentech, and Avril. The company was founded in 2006 and is headquartered in Grabels, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "France",
        "city": "Grabels"
    },
    "5NR.F": {
        "short_name": "NANOBIOTIX INH.  EO-,03",
        "long_name": "Nanobiotix S.A.",
        "summary": "Nanobiotix SA operates as a clinical-stage nanomedicine company for the treatment of cancer worldwide. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. It offers NBTXR3, a radio-enhancer hafnium oxide for the treatment of solid tumors, including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, glioblastoma, and other cancers. Nanobiotix SA was incorporated in 2003 and is headquartered in Paris, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "France",
        "city": "Paris"
    },
    "609.F": {
        "short_name": "ABIONYX PHARMA SA  EO-,05",
        "long_name": "ABIONYX Pharma SA",
        "summary": "ABIONYX Pharma SA, a biopharmaceutical company, discovers and develops high density lipoprotein (HDL) therapies for the treatment of cardiovascular and metabolic diseases. The company is developing a portfolio of HDL therapies, which include HDL mimetics for the rapid regression of atherosclerotic plaque in high-risk patients. It is developing CER-001, an engineered complex of recombinant human apoA-I, the structural protein of HDL, and phospholipids that is in Phase II clinical trials designed to mimicks the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients; and CER-209, a drug candidate that is in Phase I clinical trial for the treatment of metabolic diseases in the liver, as well as atherosclerois and non-alcoholic steato-hepatitis. The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019. ABIONYX Pharma SA was founded in 2005 and is based in Labege, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "France",
        "city": "Labege"
    },
    "609.SG": {
        "short_name": "ABIONYX PHARMA",
        "long_name": "ABIONYX Pharma SA",
        "summary": "ABIONYX Pharma SA, a biopharmaceutical company, discovers and develops high density lipoprotein (HDL) therapies for the treatment of cardiovascular and metabolic diseases. The company is developing a portfolio of HDL therapies, which include HDL mimetics for the rapid regression of atherosclerotic plaque in high-risk patients. It is developing CER-001, an engineered complex of recombinant human apoA-I, the structural protein of HDL, and phospholipids that is in Phase II clinical trials designed to mimicks the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients; and CER-209, a drug candidate that is in Phase I clinical trial for the treatment of metabolic diseases in the liver, as well as atherosclerois and non-alcoholic steato-hepatitis. The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019. ABIONYX Pharma SA was founded in 2005 and is based in Labege, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STU",
        "market": "dr_market",
        "country": "France",
        "city": "Labege"
    },
    "7PO.F": {
        "short_name": "POXEL S.A.  EO -,02",
        "long_name": "Poxel S.A.",
        "summary": "Poxel S.A., a biopharmaceutical company, develops drugs for metabolic diseases with primary focus on type II diabetes. Its lead product is Imeglimin, an oral anti-diabetic candidate, which is in Phase III clinical development stage that targets the organs of diabetes, such as pancreas, liver, and muscles. The company is also developing PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in Phase IIa clinical trial that controls body energy metabolism and treats chronic metabolic diseases, such as non-alcoholic steatohepatitis (NASH). It has a licensing agreement with Enyo Pharma for the development of PXL007 (EYP001), an FXR agonist that is in Phase I study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial pyruvate carrier inhibitor, which is in phase I clinical trials for the treatment of NASH. The company was founded in 2009 and is headquartered in Lyon, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "France",
        "city": "Lyon"
    },
    "9VO.F": {
        "short_name": "VOLUNTIS S.A.  EO-,10",
        "long_name": "Voluntis S.A.",
        "summary": "Voluntis S.A. develops digital therapeutic solutions for diabetes, oncology, and other therapeutic areas in France and the United States. It offers Insulia, a prescription medical device that provides automated basal insulin dose recommendations and coaching messages for people with type 2 diabetes; and Diabeo, a digital solution for type 1 and type 2 patients treated on a basal-bolus insulin regimen, which suggests insulin dosage, through algorithmic calculations that are specific to the patient and based on their particular doses. The company provides Oleena, a first FDA class II software-as-a-medical device for cancer indications; AstraZeneca, an e-Cediranib Olaparib application designed for patient self-reporting and management of hypertension and diarrhea; Theraxium Oncology, a cornerstone software platform for all digital therapeutics of cancer treatment, as well as coagulation and hemophilia solutions. Voluntis S.A. has a collaboration agreement with Bristol-Myers Squibb Company to co-develop digital Therapeutics for Oncology. Voluntis S.A. was founded in 2001 and is based in Suresnes, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "France",
        "city": "Suresnes"
    },
    "A89.F": {
        "short_name": "ADOCIA SAS  EO -,10",
        "long_name": "Adocia SA",
        "summary": "Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. The company's proprietary BioChaperone technological platform is designed and developed to enhance the effectiveness and/or safety of therapeutic proteins. Its clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations of insulin analog lispro; BioChaperone Combo, a combination of basal insulin glargine and rapid-acting insulin lispro; and BioChaperone Pramlintide Insulin, a prandial combination of human insulin with amylin pramlintide M1Pram. The company's clinical pipeline also includes BioChaperone Glucagon, which is an aqueous formulation of human glucagon for the treatment of hypoglycemia. Its preclinical pipeline includes BioChaperone LisPram), which is a combination of rapid human insulin analogues and Pramlintide; BioChaperone Glargine GLP1 that is a combination of insulin glargine with GLP-1 receptor agonists for the treatment of diabetes; and BioChaperone Glucagon GLP1, which is a combination of glucagon and a GLP-1 receptor agonist for the treatment of obesity. The company has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro and BioChaperone Combo in China and other Asian and Middle Eastern territories. Adocia SA was founded in 2005 and is headquartered in Lyon, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "France",
        "city": "Lyon"
    },
    "AAVXF": {
        "short_name": "ABIVAX",
        "long_name": "ABIVAX Soci\u00e9t\u00e9 Anonyme",
        "summary": "ABIVAX Soci\u00c3\u00a9t\u00c3\u00a9 Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the development of ABX 544, a drug candidate for the treatment of Ebola based on polyclonal antibodies; and research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Soci\u00c3\u00a9t\u00c3\u00a9 Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was founded in 2013 and is headquartered in Paris, France.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "France",
        "city": "Paris"
    },
    "ABNX.PA": {
        "short_name": "ABIONYX PHARMA",
        "long_name": "ABIONYX Pharma SA",
        "summary": "ABIONYX Pharma SA, a biopharmaceutical company, discovers and develops high density lipoprotein (HDL) therapies for the treatment of cardiovascular and metabolic diseases. The company is developing a portfolio of HDL therapies, which include HDL mimetics for the rapid regression of atherosclerotic plaque in high-risk patients. It is developing CER-001, an engineered complex of recombinant human apoA-I, the structural protein of HDL, and phospholipids that is in Phase II clinical trials designed to mimicks the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients; and CER-209, a drug candidate that is in Phase I clinical trial for the treatment of metabolic diseases in the liver, as well as atherosclerois and non-alcoholic steato-hepatitis. The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019. ABIONYX Pharma SA was founded in 2005 and is based in Labege, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Labege"
    },
    "ABSCF": {
        "short_name": "AB SCIENCE",
        "long_name": "AB Science S.A.",
        "summary": "AB Science S.A., a clinical-stage pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines. Its lead compound is the masitinib, a tyrosine kinase inhibitor that is in Phase III clinical trials for the treatment of prostate and pancreatic cancer, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's, severe asthma, and mastocytosis diseases. The company is also developing AB8939, synthetic microtubule destabilizer for the treatment of acute myeloid leukemia; and AB20001, which is in Phase II clinical trial to evaluate the safety and efficacy of masitinib combined with isoquercetin in hospitalized patients with moderate and severe COVID-19. The company markets its masitinib under the Masivet brand in Europe. AB Science S.A. was founded in 2001 and is headquartered in Paris, France.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers\u2014Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "France",
        "city": "Paris"
    },
    "ABVX.PA": {
        "short_name": "ABIVAX",
        "long_name": "ABIVAX Soci\u00e9t\u00e9 Anonyme",
        "summary": "ABIVAX Soci\u00c3\u00a9t\u00c3\u00a9 Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the development of ABX 544, a drug candidate for the treatment of Ebola based on polyclonal antibodies; and research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Soci\u00c3\u00a9t\u00c3\u00a9 Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was founded in 2013 and is headquartered in Paris, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Paris"
    },
    "ADOC.PA": {
        "short_name": "ADOCIA",
        "long_name": "Adocia SA",
        "summary": "Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. The company's proprietary BioChaperone technological platform is designed and developed to enhance the effectiveness and/or safety of therapeutic proteins. Its clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations of insulin analog lispro; BioChaperone Combo, a combination of basal insulin glargine and rapid-acting insulin lispro; and BioChaperone Pramlintide Insulin, a prandial combination of human insulin with amylin pramlintide M1Pram. The company's clinical pipeline also includes BioChaperone Glucagon, which is an aqueous formulation of human glucagon for the treatment of hypoglycemia. Its preclinical pipeline includes BioChaperone LisPram), which is a combination of rapid human insulin analogues and Pramlintide; BioChaperone Glargine GLP1 that is a combination of insulin glargine with GLP-1 receptor agonists for the treatment of diabetes; and BioChaperone Glucagon GLP1, which is a combination of glucagon and a GLP-1 receptor agonist for the treatment of obesity. The company has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro and BioChaperone Combo in China and other Asian and Middle Eastern territories. Adocia SA was founded in 2005 and is headquartered in Lyon, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Lyon"
    },
    "ADOCY": {
        "short_name": "ADOCIA",
        "long_name": "Adocia SA",
        "summary": "Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. The company's proprietary BioChaperone technological platform is designed and developed to enhance the effectiveness and/or safety of therapeutic proteins. Its clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations of insulin analog lispro; BioChaperone Combo, a combination of basal insulin glargine and rapid-acting insulin lispro; and BioChaperone Pramlintide Insulin, a prandial combination of human insulin with amylin pramlintide M1Pram. The company's clinical pipeline also includes BioChaperone Glucagon, which is an aqueous formulation of human glucagon for the treatment of hypoglycemia. Its preclinical pipeline includes BioChaperone LisPram), which is a combination of rapid human insulin analogues and Pramlintide; BioChaperone Glargine GLP1 that is a combination of insulin glargine with GLP-1 receptor agonists for the treatment of diabetes; and BioChaperone Glucagon GLP1, which is a combination of glucagon and a GLP-1 receptor agonist for the treatment of obesity. The company has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro and BioChaperone Combo in China and other Asian and Middle Eastern territories. Adocia SA was founded in 2005 and is headquartered in Lyon, France.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "France",
        "city": "Lyon"
    },
    "ADVIC.PA": {
        "short_name": "ADVICENNE",
        "long_name": "Advicenne S.A.",
        "summary": "Advicenne S.A., a late-stage biopharmaceutical company, develops pediatric therapeutics for the treatment of orphan renal diseases and niche neurology indications. Its lead product is ADV7103, which has completed Phase III study for the treatment of distal renal tubular acidosis in children and adults, as well as in Phase III clinical studies for the treatment of cystinuria, an inherited renal tubulopathy. The company also provides ADV6209, an oral liquid solution for children to reduce anxiety and to improve their immobility; Likozam to treat partial and generalized chronic refractory epilepsy in children and adults; and Levidcen, a granulated formulation of levetiracetam for the treatment of epilepsy in children and adults. Advicenne S.A. was founded in 2007 and is headquartered in Paris, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Paris"
    },
    "ALBIO.PA": {
        "short_name": "BIOSYNEX",
        "long_name": "Biosynex SA",
        "summary": "Biosynex SA designs, manufactures, and distributes rapid diagnostic tests in France and internationally. It offers a range of rapid diagnostic tests, immunoblots, molecular biology, and point of care products for screening, diagnosis, and prevention in the areas of bacteriology, parasitology, mycology, virology, biochemistry and oncology, and women's health, as well as instruments. The company also provides self-tests; self-measurement products, including thermometers and blood pressure monitors; and oral care and medical aid products. The company provides its products to biology and medical analysis laboratories, hospitals, pharmacies, hyper-and supermarkets, etc. It also exports its products internationally. The company was founded in 1993 and is based in Illkirch-Graffenstaden, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Illkirch-Graffenstaden"
    },
    "ALBLU.PA": {
        "short_name": "BLUELINEA",
        "long_name": "Bluelinea Soci\u00e9t\u00e9 Anonyme",
        "summary": "Bluelinea Soci\u00c3\u00a9t\u00c3\u00a9 Anonyme provides healthcare solutions for elderly and disabled people in France. The company offers SERENEA, a nursing call solution; BluePhone, a mobile phone with mobile remote assistance for seniors; BlueGard, a geolocation bracelet; prevention of night fall products; home automation solution for environmental control, opening automation, intercom/videophone, etc.; and fall and smoke detectors, call watches, and key boxes options and accessories. It also provides BlueHub packs and Handi Joysticks; IP nurse call, fugue control, autonomy bracelets, baby protection products, paging, and EHPADOM counters. The company was founded in 2006 and is headquartered in Elancourt, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Elancourt"
    },
    "ALBPS.PA": {
        "short_name": "BIOPHYTIS",
        "long_name": "Biophytis SA",
        "summary": "Biophytis SA, a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses that lead to age-related diseases. The company's lead drug candidate, Sarconeos (BIO101), is an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD). Its second drug candidate, Macuneos (BIO201), is an orally administered small molecule in development for the treatment of retinal diseases, including dry ager elated macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101). The company was founded in 2006 and is headquartered in Paris, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Paris"
    },
    "ALCAR.PA": {
        "short_name": "CARMAT",
        "long_name": "Carmat SA",
        "summary": "Carmat SA designs and develops total artificial heart for people suffering from end-stage biventricular heart failure in France and internationally. It also develops orthotopic, bioprosthetic, self-regulating, pulsatile, and implantable systems, as well as power supply systems. The company was founded in 2008 and is based in V\u00c3\u00a9lizy-Villacoublay, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "V\u00c3\u00a9lizy-Villacoublay"
    },
    "ALCJ.PA": {
        "short_name": "CROSSJECT",
        "long_name": "Crossject Soci\u00e9t\u00e9 Anonyme",
        "summary": "Crossject Soci\u00c3\u00a9t\u00c3\u00a9 Anonyme develops needle-free injection systems. The company develops ZENEO, a needle-free, prefilled, and single-use auto-injector. Its clinical stage drugs comprise Sumatriptan, which is used for of treatment migraines and cluster headaches; Adrenaline for treating anaphylactic shock; Hydrocortisone that is used for treatment of acute adrenal crisis; Midazolam for treating epileptic seizure; Naloxone used for treatment of overdose; Apomorphine, for treating temporary paralysis in parkinson's disease; Methotrexate used for treatment of rheumatoid arthritis; and Terbutaline, for treating severe asthma crisis. The company was founded in 1997 and is based in Dijon, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Dijon"
    },
    "ALCLS.PA": {
        "short_name": "CELLECTIS",
        "long_name": "Cellectis S.A.",
        "summary": "Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); ALLO-501 to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; UCART123 for the treatment of acute myeloid leukemia (AML); and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. In addition, the company produces high oleic soybean oil, other soybean products, and fiber wheat. It has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics. The company was founded in 1999 and is headquartered in Paris, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Paris"
    },
    "ALCOR.PA": {
        "short_name": "BIOCORP",
        "long_name": "Biocorp Production",
        "summary": "Biocorp Production designs, develops, and manufactures medical devices and drug delivery systems in France. The company provides Inspair, a smart cap to monitor inhalers and assesses the usage of the device; Mallya, a smart cap for pen injectors that captures injection data; Onejet, a motor driven disposable auto-injector which designs to deliver viscosity products; Datapen, a motor driven pen injector; and Injay which collects essential information, such as injection completed, time and date, type of drug, batch number, and expiration date. It also offers pharmaceutical devices, such as NEWGUARD, a safety device compatible with various sizes of needles prefilled syringes; BIOPASS, a reconstitution system; and closure systems. The company was founded in 2004 and is headquartered in Issoire, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Issoire"
    },
    "ALDEI.PA": {
        "short_name": "DEINOVE",
        "long_name": "Deinove SA",
        "summary": "DEINOVE SA, a biotech company, discovers, develops, and produces compounds originating from microbials for the health, nutrition, and cosmetics industries worldwide. The company's antibiotic candidates include DNV3837, an antibiotic, which is in the Phase II clinical trial for the treatment of Clostridioides difficile infections. It also offers PHYT-N-Resist, an anti-aging active ingredient for cosmetics; Luminity, a carotenoid-based ingredient to absorb blue light and exceptional antioxidant properties; HEBELYS, a natural active ingredient produced by fermentation of Sphingomonas; and BIOME Ol\u00c3\u00a9oactif, which acts as a post-biotic extract with a prebiotic effect to balance the skin microbiota. In addition, the company develops a process for producing natural ingredients for animal feed. DEINOVE SA has partnership agreements primarily with bioM\u00c3\u00a9rieux, Naicons, Medpace, Institut Pasteur, Hallstar Group, Sharon Laboratories, Ol\u00c3\u00a9os-Hallstar, Greentech, and Avril. The company was founded in 2006 and is headquartered in Grabels, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Grabels"
    },
    "ALECR.PA": {
        "short_name": "EUROFINS CEREP",
        "long_name": "Eurofins-Cerep SA",
        "summary": "Eurofins Cerep SA provides various drug discovery services to pharmaceutical and biotechnology companies worldwide. The company's research services include compound management, high-throughput screening, in vitro safety profiling, lead optimization (or SAR) profiling, in vitro ADME profiling, and in vivo PK. It also offers assay design and development services. The company was formerly known as Cerep SA and changed its name to Eurofins Cerep SA in June 2014. Eurofins Cerep SA was founded in 1989 and is based in Vienne, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers\u2014General",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Vienne"
    },
    "ALEMG.PA": {
        "short_name": "EUROMEDIS GROUPE",
        "long_name": "Euromedis Groupe",
        "summary": "Euromedis Groupe, together with its subsidiaries, designs, manufactures, and distributes medical equipment under the Euromedis brand for hospitals, clinics, retirement homes, physicians, pharmacies, and individuals in France. It offers disposable medical gloves; surgical products, such as sensors, pockets, scalpels, etc.; hygiene and protection equipment comprising white-coats, masks, shoes, etc.; needles, syringes, infusers, catheters, transfusion equipment, etc.; and compresses, bandages, beds, etc. The company also provides incontinence products, as well as products related to hygiene; and home care products. In addition, it distributes medical-surgical equipment through a network of outlets under the Paramat name. Further, the company leases equipment; and provides home maintenance and hospitalization services. It also exports its products to Belgium, Italy, Morocco, Ivory Coast, Gabon, Benin, Algeria, Ireland, the Netherlands, Portugal, Tunisia, Switzerland, the Czech Republic, the United Kingdom, Germany, Finland, Spain, Greece, Hungary, Lithuania, Latvia, Bulgaria, and Poland. Euromedis Groupe was founded in 1985 and is based in Mouy, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Mouy"
    },
    "ALERS.PA": {
        "short_name": "EUROBIO-SCIENTIFIC",
        "long_name": "Eurobio Scientific Soci\u00e9t\u00e9 anonyme",
        "summary": "Eurobio Scientific Soci\u00c3\u00a9t\u00c3\u00a9 anonyme discovers and commercializes specialty diagnostic products in the areas of transplantation, infectious diseases, life-science, and cancer. The company offers Tetanus Quick Stick, a test that is used in emergency clinics for the determination of the tetanus vaccination status of a patient; and commercializes cell culture media, molecular biology reagents, and proprietary antibodies. Its in-house development products include the BJI InoPlex, a multiplex serological test used for the diagnosis of prosthetic joint infections; and licensed products comprise AlloMap, a gene-expression profiling based blood test for the surveillance of heart-transplant patients. The company was formerly known as Diaxonhit and changed its name to Eurobio Scientific Soci\u00c3\u00a9t\u00c3\u00a9 anonyme in June 2018. Eurobio Scientific Soci\u00c3\u00a9t\u00c3\u00a9 anonyme was founded in 1997 and is headquartered in Les Ulis, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Les Ulis"
    },
    "ALGEN.PA": {
        "short_name": "GENOWAY",
        "long_name": "genOway Soci\u00e9t\u00e9 anonyme",
        "summary": "genOway S.A., a biotechnology company, engages in the development and sale of custom genetically-modified mouse, rat, and cellular models worldwide. The company provides technological solutions for transgenesis and model design. It produces custom mouse models, such as knockout (KO) and knockin (KI) mouse models; custom rat models; custom cell models; catalog models; and phenotyping for in vivo or in vitro studies. The company also provides patented homologous recombination technology for the generation of genetically modified rodent models; CRISPR/Cas9 nuclease systems for the KO and KI model creation; and FLEx, an inducible point mutation technology that allows scientists to induce the expression of a mutated gene or a reporter gene during the lifetime of the animal model. In addition, it offers tetracycline on/off systems to control gene expression; and internal ribosome entry site technology to generate multigenic-based disease models, reporter models, cell lineage tracking models, and tissue-specific Cre driver lines, as well as to monitor cell expression patterns in KO models. Further, the company provides recombinase-mediated cassette exchange technology to enable the swapping of genomic regions; and Quick Knockin technology, such as Rosa26, Hprt, and AAVS1. It serves pharmaceutical and life science companies, and academic institutes. genOway S.A. has a strategic alliance with Merck to develop and validate new CRISPR/Cas9-related products and solutions. The company was founded in 1999 and is based in Lyon, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Lyon"
    },
    "ALHYG.PA": {
        "short_name": "HYBRIGENICS",
        "long_name": "Hybrigenics Soci\u00e9t\u00e9 Anonyme",
        "summary": "Hybrigenics Soci\u00c3\u00a9t\u00c3\u00a9 Anonyme comprises biopharmaceutical company. Hybrigenics Soci\u00c3\u00a9t\u00c3\u00a9 Anonyme is located in France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "None"
    },
    "ALICR.PA": {
        "short_name": "I.CERAM",
        "long_name": "I.CERAM SA",
        "summary": "I.CERAM SA designs, manufactures, and markets alumina bio-ceramic implants in France and internationally. It offers implants for various joints of the human body, including ankle, knee, hip, spine, shoulder, wrist, skull, tibia, and foot, as well as osteosynthesis products. The company was founded in 2005 and is based in Limoges, France. I.CERAM SA is a subsidiary of Investissement D\u00c3\u00a9veloppement.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Limoges"
    },
    "ALIMP.PA": {
        "short_name": "IMPLANET",
        "long_name": "Implanet S.A.",
        "summary": "Implanet S.A., together with its subsidiaries, designs, manufactures, and sells implants for orthopedic surgery in France, the United States, Brazil, and internationally. The company offers spinal, arthroscopy, and knee products. Its products include Jazz, Jazz Passer, Jazz Cap SP, Jazz Lock, Jazz Claw, Jazz Standalone, Jazz Frame, and Jazz Screw systems for posterior fixation. The company also offers knee prostheses, such as Madison for conventional surgical techniques. Implanet S.A. was founded in 2006 and is based in Martillac, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Martillac"
    },
    "ALINS.PA": {
        "short_name": "INTRASENSE",
        "long_name": "Intrasense SA",
        "summary": "Intrasense SA designs and develops software solution for advanced visualization and analysis of multimodality medical images under the Myrian name. The company offers Myrian Imaging Layer, a multimodal visualization software platform suite for health industrials; Myrian Studio, a solution for the development of medical imaging applications for innovators, industrial clients, research labs, and spin-offs; and Myrian technologies to develop biomarkers and artificial intelligence solutions. It also provides Myrian Clinical Apps, a portfolio of clinical applications for advanced post-processing, which include Myrian XL-Onco, a lesion tracking solutions; Myrian XP-Prostate; Myrian XP-Breast; Myrian XP-Liver; Myrian XP-Mammo; Myrian XP-Lung; Myrian XP-Colon; Myrian XP-Vessel; Myrian XP-Cardiac; solution for pathology or organ; and various tools for the analysis of MRI, CT, conventional, radiology, and nuclear imaging exams. The company was founded in 2004 and is headquartered in Montpellier, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Montpellier"
    },
    "ALINT.PA": {
        "short_name": "INTEGRAGEN",
        "long_name": "IntegraGen SA",
        "summary": "As of October 21, 2020, IntegraGen SA operates as a subsidiary of OncoDNA SA.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Evry"
    },
    "ALMDT.PA": {
        "short_name": "MEDIANTECHNOLOGIES",
        "long_name": "Median Technologies SA",
        "summary": "Median Technologies SA develops and markets software products and platforms for medical image analysis in France, the United States, Canada, the United Kingdom, China, and internationally. The company offers iBiopsy (Imaging BIOmarker Phenotyping System), a phenomics imaging platform empower translational research with AI powered Biomarker identification tools and inform clinical decisions using CT scan similarity search for patient profiling services; and iSee for image analysis and management in clinical trials. It also provides imaging contract research services, such as study start up, image and clinical data management, scientific consulting, independent reviews, image data processing and site support, and study close-out for studies. The company was founded in 2002 and is based in Valbonne, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Valbonne"
    },
    "ALNEV.PA": {
        "short_name": "NEOVACS",
        "long_name": "Neovacs S.A.",
        "summary": "Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Paris"
    },
    "ALONC.PA": {
        "short_name": "ONCODESIGN",
        "long_name": "Oncodesign Soci\u00e9t\u00e9 Anonyme",
        "summary": "Oncodesign Soci\u00c3\u00a9t\u00c3\u00a9 Anonyme, a biopharmaceutical company, conducts research and development work on new therapeutic and diagnostic tools with pharmaceutical firms, biotech companies, public research institutions, and investment groups. It offers integrated drug discovery services; in vitro and in vivo pharmacology services; services for studying the metabolism and pharmacokinetics of drug candidates; and translational biomarkers, biodecontamination/biosafety, and biobanking services. The company also engages in the analysis of new chemical and biological entities, and membrane proteins; and immuno analysis and monitoring, and microbiological monitoring activities. In addition, it engages in the kinase inhibitor development programs, and licensing of Kinase inhibitors in oncology, and CNS and inflammation technologies. The company was founded in 1995 and is headquartered in Dijon, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Dijon"
    },
    "ALONX.PA": {
        "short_name": "ONXEO",
        "long_name": "Onxeo SA",
        "summary": "Onxeo SA, a clinical-stage biotechnology company, designs and develops oncology drugs for tumor DNA repair functions worldwide. The company offers Beleodaq for the treatment of relapsed or refractory peripheral T-cell lymphoma. It also develops AsiDNA, which is in Phase 1 clinical trial for the treatment of metastatic melanoma; OX401, which is in preclinical stage for treating DNA damage response and immuno-oncology; and Validive, which completed Phase II clinical trial for the treatment of oral mucositis in patients treated for a head and neck cancer. Onxeo SA has a collaboration and licensing agreement with Spectrum Pharmaceuticals for the development of Beleodaq; a license agreement with Monopar Therapeutics Inc. to develop Validive; and clinical research agreement with Gustave Roussy to conduct clinical trial of AsiDNA for the treatment of relapsed ovarian cancer. The company was formerly known as BioAlliance Pharma SA and changed its name to Onxeo SA in July 2014. Onxeo SA was founded in 1997 and is headquartered in Paris, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Paris"
    },
    "ALPAT.PA": {
        "short_name": "PLANT ADVANCED",
        "long_name": "Plant Advanced Technologies SA",
        "summary": "Plant Advanced Technologies SA, a plant biotechnology company, produces and sells actives for cosmetic, pharmaceutical, and agrochemical markets in France. The company's technologies include PAT Plant Milking that produces active extracts through plant stimulation and living-root exudation while preserving plants; PAT Target Binding, which finds the ligands that bind to the protein targets of interest, such as enzymes; and PAT Friday, a recombinant protein expression system using natural protein excretion system of genetically modified carnivorous plants to produce outside their leaf in a sterile closed pitcher. Plant Advanced Technologies SA was founded in 2005 and is headquartered in Vand\u00c2\u009cuvre-l\u00c3\u00a8s-Nancy, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Vand\u00c5\u0093uvre-l\u00c3\u00a8s-Nancy"
    },
    "ALPHA.PA": {
        "short_name": "PHARNEXT",
        "long_name": "Pharnext SA",
        "summary": "Pharnext SA, a clinical-stage biopharmaceutical company, develops therapies for orphan and common neurodegenerative diseases in France. The company's products include SYNGILITY that has completed Phase III trial for the treatment of Charcot-Marie-Tooth disease type 1A; and PXT864, which has completed Phase II clinical trial to treat Alzheimer's disease, as well as Parkinson's disease and amyotrophic lateral sclerosis. It also develops PLEOTHERAPY, a big genetic data and artificial intelligence platform. Pharnext SA has an agreement with the University Hospital Institute Mediterranee Infection to evaluate repurposed drugs for potential use against the COVID-19 virus. The company was founded in 2007 and is headquartered in Issy-Les-Moulineaux, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Issy-les-Moulineaux"
    },
    "ALPIX.PA": {
        "short_name": "PIXIUM VISION",
        "long_name": "Pixium Vision SA",
        "summary": "Pixium Vision SA, a bioelectronics and brain machine interface technology company, specialized in neuromodulation application. It develops PRIMA System, a bionic vision system to treat blindness caused by degeneration of photoreceptor cells in the retina. The company has collaboration agreements with Stanford University in California, Institut de la Vision, Moorfields Eye Hospital, Institute of Ocular Microsurgery, University Hospital, and UPMC. Pixium Vision SA was founded in 2011 and is based in Paris, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Paris"
    },
    "ALPRE.PA": {
        "short_name": "PREDILIFE",
        "long_name": "Predilife S.A.",
        "summary": "Predilife S.A. develops and sells medical techniques and mathematical models. The company provides genetic testing, medical imaging, etc. Its product, MammoRisk, is a test for predicting the development of breast cancer based on the patient's individual risk. The company has a partnership agreement with Institut Curie for genetic analyses for MammoRisk. Predilife S.A. was founded in 2004 and is based in Villejuif, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Villejuif"
    },
    "ALQGC.PA": {
        "short_name": "QUANTUM GENOMICS",
        "long_name": "Quantum Genomics Soci\u00e9t\u00e9 Anonyme",
        "summary": "Quantum Genomics Soci\u00c3\u00a9t\u00c3\u00a9 Anonyme, a biopharmaceutical company, develops drugs to treat cardiovascular diseases. It develops drugs primarily to treat high blood pressure and heart failure. The company develops firibastat, a monotherapy drug for the treatment of hypertension and heart failure, as well as acts on the inhibition of Aminopeptidase A in the brain. It is also developing QGC011 that is in pre-clinical phase to treat hypertension with combination therapy; and QGC006 to optimize the treatment of hypertension with a monotherapy drug. The company is based in Paris, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Paris"
    },
    "ALSAF.PA": {
        "short_name": "SAFE ORTHOPAEDICS",
        "long_name": "Safe Orthopaedics SA",
        "summary": "Safe Orthopaedics SA, a medical technology company, develops and markets sterile implants and single-use instruments for the treatment of spinal fracture pathologies in France and internationally. The company offers SteriSpine PS, an all-round kit for the treatment of spinal fractures and degenerative pathologies; and SteriSpine VA, a product platform for ready to use Kyphoplasty and Cement systems. It also provides SteriSpine LC, a ready to use instrumentation for lumbar cage portfolio, including Cedar and Elm; and SteriSpine CC, a ready to use instrumentation for cervical cage, such as Walnut. The company was founded in 2010 and is headquartered in \u00c3\u0089ragny-sur-Oise, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Eragny-sur-Oise"
    },
    "ALSEN.PA": {
        "short_name": "SENSORION",
        "long_name": "Sensorion SA",
        "summary": "Sensorion SA, a biopharmaceutical company, develops therapies for the treatment of inner ear disorders. The company develops SENS-111, which is in phase II clinical trials to treat acute unilateral vestibulopathy; and SENS-401 that is in phase I clinical trials to treat sudden sensorineural hearing loss. It also develops SENS-300, which is under the pre-clinical stage for use in inner ear toxicity treatment. The company has a strategic collaboration with Cochlear Limited to study combination therapies for cochlear implant patients. Sensorion SA was founded in 2009 and is headquartered in Montpellier, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Montpellier"
    },
    "ALSGD.PA": {
        "short_name": "SPINEGUARD",
        "long_name": "SpineGuard SA",
        "summary": "SpineGuard SA provides designs, develops, and markets medical devices used in surgical procedures worldwide. The company provides PediGuard Straight probe for screw placement; PediGuard Curved probe that includes a tapered tip to enhance the ease of penetrating through bone; PediGuard Cannulated probe primarily for helping surgeons reduce radiation exposure during minimally-invasive (percutaneous) procedures; and PediGuard Threaded Device, a drilling instrument. It also offers DSG(Dynamic Surgical Guidance) Connect app, which allows collection and visualization of the signal measured at the tip of DSG connect devices during pedicle drilling; and DSG smart screw allows for one step screw placement treatment. The company serves patients, surgeons, operating room staff, and health care providers. SpineGuard SA was founded in 2009 and is headquartered in Vincennes, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Vincennes"
    },
    "ALSPW.PA": {
        "short_name": "SPINEWAY",
        "long_name": "Spineway Soci\u00e9t\u00e9 Anonyme",
        "summary": "Spineway Soci\u00c3\u00a9t\u00c3\u00a9 Anonyme engages in the design, manufacture, and marketing of implant lines and surgical equipment for treating spinal column pathologies. The company offers Ayers Rock, an anterior cervical interbody fusion cage; Blue Mountain, an anterior cervical interbody fusion plate; Mont Blanc, a posterior thoracolumbar system; Mont Blanc Baby, a posterior thoracolumbar pediatric system; Mont Blanc 3D+, a posterior for direct correction; Kili, an anterior lumbar interbody fusion cage; Twin peaks PLIF bullet shaped posterior lumbar interbody fusion cages; Twin peaks OLIF oblique lumbar interbody fusion cages; Twin peaks TLIF transforaminal lumbar interbody fusion cages; and Mont Blanc MIS, a mini-invasive thoracolumbar system. It also provides Sonora and Neve bone substitutes; Rift lumbar and Rift cervical instrumentation for spinal surgery; and Rift invasive solution. In addition, the company exports its products to approximately 50 countries through distributors. Spineway Soci\u00c3\u00a9t\u00c3\u00a9 Anonyme was founded in 2005 and is headquartered in Ecully, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Ecully"
    },
    "ALSSI.PA": {
        "short_name": "SUPERSONIC IMAGINE",
        "long_name": "SuperSonic Imagine SA",
        "summary": "SuperSonic Imagine SA operates as a medical technology company. It designs, develops, and markets Aixplorer, an ultrasound system. It has developed a technology that offers practitioners and patients a breakthrough in the diagnosis and follow up of breast, prostate, and thyroid cancers, as well as liver diseases. The company's products include Aixplorer, an ultrasound system that renders images with exceptional definition, contrast, and resolution. It operates primarily in China, the United States, and France. The company was founded in 2005 and is headquartered in Aix-en-Provence, France. SuperSonic Imagine SA is a subsidiary of Hologic Hub Ltd.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Aix-en-Provence"
    },
    "ALTHE.PA": {
        "short_name": "THERACLION",
        "long_name": "Theraclion Soci\u00e9t\u00e9 anonyme",
        "summary": "Theraclion Soci\u00c3\u00a9t\u00c3\u00a9 anonyme develops, manufactures, and markets therapeutic ultrasound equipment. It offers an echotherapy solution that combines high-intensity focused ultrasound therapy with ultrasound as a system for locating target areas for the non-invasive treatment of benign tumours. The company also offers Echopulse for the non-invasive and ambulatory treatment of breast fibroadenomas and benign thyroid nodules to practitioners; and SONOVEIN, an echotherapy solution using therapeutic ultrasound for the treatment of varicose veins. It operates in approximately 20 countries worldwide. The company was founded in 2004 and is based in Malakoff, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Malakoff"
    },
    "ALTHX.PA": {
        "short_name": "THERANEXUS",
        "long_name": "Theranexus Soci\u00e9t\u00e9 Anonyme",
        "summary": "Theranexus soci\u00c3\u00a9t\u00c3\u00a9 anonyme, a biopharmaceutical company, develops drug candidates for the treatment of central nervous system disorders. The company's lead drug candidate is THN102, which is in Phase II clinical trial to treat sleep/wake disorders. It also develops THN201 for the treatment of neurocognitive disorders linked to Alzheimer's disease; and THN101 to treat neuropathic pain. The company was founded in 2013 and is based in Lyon, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Lyon"
    },
    "ALVAL.PA": {
        "short_name": "VALBIOTIS",
        "long_name": "Valbiotis SA",
        "summary": "Valbiotis SA develops nutrition solutions to prevent cardio metabolic diseases and provides nutritional support for patients. The company develops Valedia, a product that is in Phase II clinical trial for the treatment of type 2 diabetes. The company also develops VAL-63, a health supplement that is used for the prevention of non-alcoholic fatty liver disease; and VAL-630, a medical nutrition product for providing nutritional support for patients with non-alcoholic steatohepatitis and type 2 diabetes. In addition, the company's products under clinical development comprise Lipidrive that regulates body weight by acting specifically on body fat mass; and VAL-070, which reduces lipid dysfunctions cholesterol, a risk factor for cardiovascular disease. Valbiotis SA was founded in 2014 and is based in P\u00c3\u00a9rigny, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "P\u00c3\u00a9rigny"
    },
    "ALVMG.PA": {
        "short_name": "VISIOMED GROUP",
        "long_name": "Visiomed Group SA",
        "summary": "Visiomed Group SA develops and distributes electronic medical devices in Europe and internationally. It provides thermometers, blood pressure monitors, pulse oximeters, connected blood glucometers, and connected electrocardiograms; and pain relief products, such as electrotherapy. The company also offers connected scales and scalable baby scales, as well as prevention and treatment products, such as humidifiers and phototherapies. In addition, it provides hearing products and optics, including presbycusis, as well as family hygiene products. The company offers its products under the ThermoFlash, T. LeClerc, Visiocheck, Innoxa, and BewellConnect brands. Visiomed Group SA was founded in 2007 and is headquartered in Paris, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Paris"
    },
    "AMPLI.PA": {
        "short_name": "AMPLITUDE SURGICAL",
        "long_name": "Amplitude Surgical SA",
        "summary": "Amplitude Surgical SA develops and markets products for orthopedic surgery. The company provides a range of orthopedic products for primary and revision surgery aimed at treating pathologies of the hip, knee, and lower extremities primarily for foot and ankle surgery. It offers knee and hip prostheses and implants for the foot and ankle. The company also provides AMPLIVISION, a computer-assisted surgical system; the i.M.A.G.E., a single-use made-to-measure instrument system; and the E.T.O.I.L.E, a technology platform for anterior approaches resulting in less-invasive surgery. In addition, it offers instruments for fitting implants. The company sells its products through a network of distributors and agents in approximately 30 countries. It serves patients, surgeons, and healthcare facilities. Amplitude Surgical SA was founded in 1997 and is headquartered in Valence, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Valence"
    },
    "AYJ.F": {
        "short_name": "VALNEVA SE  EO -,15",
        "long_name": "Valneva SE",
        "summary": "Valneva SE, a specialty vaccine company, engages in developing and commercializing vaccines for infectious diseases with unmet needs. Its portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT indicated for the prevention of Japanese encephalitis; and DUKORAL indicated for the prevention of cholera and in some countries prevention of diarrhea caused by ETEC. The company has various vaccines in development, including a vaccine against Lyme disease and single-shot vaccine against chikungunya. It has operations in Austria, Canada, France, Sweden, the United Kingdom, and the United States. The company has collaboration with Dynavax Technologies Corporation to advance vaccine development for COVID-19. Valneva SE was incorporated in 1999 and is headquartered in Nantes, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "France",
        "city": "Nantes"
    },
    "BLC.PA": {
        "short_name": "BASTIDE LE CONFORT",
        "long_name": "Bastide Le Confort M\u00e9dical SA",
        "summary": "Bastide Le Confort M\u00c3\u00a9dical SA engages in the sale and rental of medical equipment in France. The company offers comfort and health products, such as lift chairs, bathroom and well-being products, pillows and cushions, seats, phones keys, measuring devices, technical aids, fitness products, blood pressure monitors, and pillboxes ; and incontinence products, including absorbent and support briefs, anatomical protections, protections for men and women, disposable mattress pads, PVC panties, and hygiene and body care products. It also provides medical materials comprising home support products wheel chairs, electric scooters, walkers, bed tables and rails, and transfer aids, air mattress, sick lifts, and standers; and medical equipment consisting of consumables, care and dressings, hygiene and disinfection products, outfits and briefcases, and other medical equipment, as well as home support services for elderly, senior, or disabled. It offers its products through approximately 130 stores, as well as through an online store. The company was founded in 1977 and is headquartered in Caissargues, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Distribution",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Caissargues"
    },
    "BMXMF": {
        "short_name": "BIOMERIEUX",
        "long_name": "bioM\u00e9rieux S.A.",
        "summary": "bioM\u00c3\u00a9rieux S.A. provides vitro diagnostic solutions systems for private and hospital laboratories, primarily for the diagnosis of infectious diseases. The company offers microbiology technology that identifies microorganism present in biological samples; and immunoassays technology based on antigen-antibody reaction, detects and measures infectious agents, such as bacteria, viruses, and parasites, as well as pathological markers. It also provides molecular biology for the detection of genetic sequences of deoxyribonucleic acid or ribonucleic acid; and companion diagnostic test, as well as services for clinical and industrial laboratories. The company was formerly known as B-D M\u00c3\u00a9rieux. bioM\u00c3\u00a9rieux S.A. was founded in 1963 and is headquartered in Marcy l'Etoile, France. bioM\u00c3\u00a9rieux S.A. is a subsidiary of Institut M\u00c3\u00a9rieux SA.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PNK",
        "market": "us_market",
        "country": "France",
        "city": "Marcy l'\u00c3\u0089toile"
    },
    "BOI.PA": {
        "short_name": "BOIRON",
        "long_name": "Boiron SA",
        "summary": "Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers non-proprietary homeopathic medicines; and proprietary, branded homeopathic medicines. Its branded homeopathic medicines include Oscillococcinum to treat flu like symptoms, such as fever, chills, headaches, and aches; Stodal and Stodaline for treating coughs; Arnigel for adjunctive local treatment of benign trauma in the absence of open wounds; Camilia for the treatment of teething problems for babies; and S\u00c3\u00a9datif PC to treat anxiety and emotional, and minor sleep disorders. The company's branded homeopathic medicines also comprise Coryzalia for the treatment of cold symptoms and rhinitis; Hom\u00c3\u00a9optic to treat ocular discomfort and irritation due to various causes for adults and children; and Hom\u00c3\u00a9ovox for vocal disorders. It offers its products through distribution centers, pharmacy chains, wholesalers, supermarkets, drugstores, and health food stores. Boiron SA was founded in 1932 and is headquartered in Messimy, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers\u2014Specialty & Generic",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Messimy"
    },
    "BOIRF": {
        "short_name": "BOIRON",
        "long_name": "Boiron SA",
        "summary": "Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers non-proprietary homeopathic medicines; and proprietary, branded homeopathic medicines. Its branded homeopathic medicines include Oscillococcinum to treat flu like symptoms, such as fever, chills, headaches, and aches; Stodal and Stodaline for treating coughs; Arnigel for adjunctive local treatment of benign trauma in the absence of open wounds; Camilia for the treatment of teething problems for babies; and S\u00c3\u00a9datif PC to treat anxiety and emotional, and minor sleep disorders. The company's branded homeopathic medicines also comprise Coryzalia for the treatment of cold symptoms and rhinitis; Hom\u00c3\u00a9optic to treat ocular discomfort and irritation due to various causes for adults and children; and Hom\u00c3\u00a9ovox for vocal disorders. It offers its products through distribution centers, pharmacy chains, wholesalers, supermarkets, drugstores, and health food stores. Boiron SA was founded in 1932 and is headquartered in Messimy, France.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers\u2014Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "France",
        "city": "Messimy"
    },
    "BON.F": {
        "short_name": "BOIRON SA INH.  EO 1",
        "long_name": "Boiron SA",
        "summary": "Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers non-proprietary homeopathic medicines; and proprietary, branded homeopathic medicines. Its branded homeopathic medicines include Oscillococcinum to treat flu like symptoms, such as fever, chills, headaches, and aches; Stodal and Stodaline for treating coughs; Arnigel for adjunctive local treatment of benign trauma in the absence of open wounds; Camilia for the treatment of teething problems for babies; and S\u00c3\u00a9datif PC to treat anxiety and emotional, and minor sleep disorders. The company's branded homeopathic medicines also comprise Coryzalia for the treatment of cold symptoms and rhinitis; Hom\u00c3\u00a9optic to treat ocular discomfort and irritation due to various causes for adults and children; and Hom\u00c3\u00a9ovox for vocal disorders. It offers its products through distribution centers, pharmacy chains, wholesalers, supermarkets, drugstores, and health food stores. Boiron SA was founded in 1932 and is headquartered in Messimy, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers\u2014Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "France",
        "city": "Messimy"
    },
    "C4X.F": {
        "short_name": "ONXEO S.A. AC.PORT.EO-,25",
        "long_name": "Onxeo SA",
        "summary": "Onxeo SA, a clinical-stage biotechnology company, designs and develops oncology drugs for tumor DNA repair functions worldwide. The company offers Beleodaq for the treatment of relapsed or refractory peripheral T-cell lymphoma. It also develops AsiDNA, which is in Phase 1 clinical trial for the treatment of metastatic melanoma; OX401, which is in preclinical stage for treating DNA damage response and immuno-oncology; and Validive, which completed Phase II clinical trial for the treatment of oral mucositis in patients treated for a head and neck cancer. Onxeo SA has a collaboration and licensing agreement with Spectrum Pharmaceuticals for the development of Beleodaq; a license agreement with Monopar Therapeutics Inc. to develop Validive; and clinical research agreement with Gustave Roussy to conduct clinical trial of AsiDNA for the treatment of relapsed ovarian cancer. The company was formerly known as BioAlliance Pharma SA and changed its name to Onxeo SA in July 2014. Onxeo SA was founded in 1997 and is headquartered in Paris, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "France",
        "city": "Paris"
    },
    "C7E.F": {
        "short_name": "CEGEDIM SA  EO 0,9528",
        "long_name": "Cegedim SA",
        "summary": "Cegedim SA operates as a technology and services company in the digital data flow management for healthcare ecosystem and B2B marketing, and business software for healthcare and insurance professionals worldwide. It operates through two divisions, Health Insurance, HR and e-Services; and Healthcare Professionals. The Health Insurance, HR and e-Services division markets various products and services to insurance companies, mutual insurers, personal protection insurers, and insurance brokers, as well as engages in the interactions between these entities and healthcare professionals. This division also offers software and services for health insurers; flows, electronic payment, and management services; and outsourced payroll and human resources management services, as well as electronic data exchange services. In addition, it provides digital marketing tools to doctors, pharmacists, and allied health professionals; digital displays in pharmacies, and health and wellness shops; digitization of business, accounting, financial, and communication data flows; data and analytics for the healthcare industry; and other services, including the management of medical samples and promotional materials, healthcare data hosting, and integration and services. The Healthcare Professionals division offers management software, databases, and solutions to doctors, allied health professionals, pharmacists, and healthcare facilities. The company was founded in 1969 and is headquartered in Boulogne-Billancourt, France. Cegedim SA is a subsidiary of FCB SAS.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "France",
        "city": "Boulogne-Billancourt"
    },
    "CGM.PA": {
        "short_name": "CEGEDIM",
        "long_name": "Cegedim SA",
        "summary": "Cegedim SA operates as a technology and services company in the digital data flow management for healthcare ecosystem and B2B marketing, and business software for healthcare and insurance professionals worldwide. It operates through two divisions, Health Insurance, HR and e-Services; and Healthcare Professionals. The Health Insurance, HR and e-Services division markets various products and services to insurance companies, mutual insurers, personal protection insurers, and insurance brokers, as well as engages in the interactions between these entities and healthcare professionals. This division also offers software and services for health insurers; flows, electronic payment, and management services; and outsourced payroll and human resources management services, as well as electronic data exchange services. In addition, it provides digital marketing tools to doctors, pharmacists, and allied health professionals; digital displays in pharmacies, and health and wellness shops; digitization of business, accounting, financial, and communication data flows; data and analytics for the healthcare industry; and other services, including the management of medical samples and promotional materials, healthcare data hosting, and integration and services. The Healthcare Professionals division offers management software, databases, and solutions to doctors, allied health professionals, pharmacists, and healthcare facilities. The company was founded in 1969 and is headquartered in Boulogne-Billancourt, France. Cegedim SA is a subsidiary of FCB SAS.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Boulogne-Billancourt"
    },
    "CLLS": {
        "short_name": "Cellectis S.A.",
        "long_name": "Cellectis S.A.",
        "summary": "Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); ALLO-501 to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; UCART123 for the treatment of acute myeloid leukemia (AML); and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. In addition, the company produces high oleic soybean oil, other soybean products, and fiber wheat. It has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics. The company was founded in 1999 and is headquartered in Paris, France.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "France",
        "city": "Paris"
    },
    "CMVLF": {
        "short_name": "CELLECTIS",
        "long_name": "Cellectis S.A.",
        "summary": "Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); ALLO-501 to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; UCART123 for the treatment of acute myeloid leukemia (AML); and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. In addition, the company produces high oleic soybean oil, other soybean products, and fiber wheat. It has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics. The company was founded in 1999 and is headquartered in Paris, France.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "France",
        "city": "Paris"
    },
    "COX.PA": {
        "short_name": "NICOX",
        "long_name": "Nicox S.A.",
        "summary": "Nicox S.A., an ophthalmology company, develops solutions to maintain ocular health in France and internationally. It offers VYZULTA, a latanoprostene bunod ophthalmic solution for open angle glaucoma or ocular hypertension; ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis; and NCX 4280, an ophthalmic solution that targets morning eye congestion. The company also develops NCX 470, a nitric oxide (NO)-donating candidate that is in Phase II clinical trial for the lowering of intraocular pressure in patients with open angle glaucoma or ocular hypertension; and NCX 4251, a patented formulation of fluticasone propionate, which is in Phase II clinical trial for patients with acute exacerbations of blepharitis. Its research product pipeline includes NO-donating phosphodiesterase-5 inhibitors. The company has collaborations with Bausch + Lomb and Ironwood Pharmaceuticals, Inc. Nicox S.A. was founded in 1996 and is headquartered in Valbonne, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Valbonne"
    },
    "CXT.F": {
        "short_name": "CARMAT  EO -,04",
        "long_name": "Carmat SA",
        "summary": "Carmat SA designs and develops total artificial heart for people suffering from end-stage biventricular heart failure in France and internationally. It also develops orthotopic, bioprosthetic, self-regulating, pulsatile, and implantable systems, as well as power supply systems. The company was founded in 2008 and is based in V\u00c3\u00a9lizy-Villacoublay, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "France",
        "city": "V\u00c3\u00a9lizy-Villacoublay"
    },
    "DBV.F": {
        "short_name": "DBV TECHNOLOGIES  EO -,10",
        "long_name": "DBV Technologies S.A.",
        "summary": "DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestl\u00c3\u00a9 Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "France",
        "city": "Montrouge"
    },
    "DBV.PA": {
        "short_name": "DBV TECHNOLOGIES",
        "long_name": "DBV Technologies S.A.",
        "summary": "DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestl\u00c3\u00a9 Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Montrouge"
    },
    "DBVA.F": {
        "short_name": "DBV TECH.SP.ADR 1/2 EO-10",
        "long_name": "DBV Technologies S.A.",
        "summary": "DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestl\u00c3\u00a9 Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "France",
        "city": "Montrouge"
    },
    "DBVT": {
        "short_name": "DBV Technologies S.A.",
        "long_name": "DBV Technologies S.A.",
        "summary": "DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestl\u00c3\u00a9 Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "France",
        "city": "Montrouge"
    },
    "DGM.PA": {
        "short_name": "DIAGNOSTIC MEDICAL",
        "long_name": "Diagnostic Medical Systems S.A.",
        "summary": "Diagnostic Medical Systems S.A. operates in the medical imaging industry in France. It offers radiography/fluoroscopy, retrofit kits, mammography, chest and bone rooms, mobiles, bone densitometry, 3D reconstruction, mobile C-arms, and posturology solutions. The company also exports its products. Diagnostic Medical Systems S.A. was founded in 1993 and is based in Mauguio, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Mauguio"
    },
    "DIM.PA": {
        "short_name": "SARTORIUS STED BIO",
        "long_name": "Sartorius Stedim Biotech S.A.",
        "summary": "Sartorius Stedim Biotech S.A. produces and sells instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; and a range of products for separation, purification, and concentration processes, as well as systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, filtration, purification, fluid management services, and membrane chromatography services. In addition, the company offers data analytics software for modeling and optimizing processed of biopharmaceutical development and production. It serves manufacturers of pharmaceuticals, foods, and chemicals, as well as research and development laboratories. The company was founded in 1870 and is headquartered in Aubagne, France. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Aubagne"
    },
    "DIM.VI": {
        "short_name": "SARTORIUS STEDIM BIOTECH",
        "long_name": "Sartorius Stedim Biotech S.A.",
        "summary": "Sartorius Stedim Biotech S.A. produces and sells instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; and a range of products for separation, purification, and concentration processes, as well as systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, filtration, purification, fluid management services, and membrane chromatography services. In addition, the company offers data analytics software for modeling and optimizing processed of biopharmaceutical development and production. It serves manufacturers of pharmaceuticals, foods, and chemicals, as well as research and development laboratories. The company was founded in 1870 and is headquartered in Aubagne, France. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "VIE",
        "market": "at_market",
        "country": "France",
        "city": "Aubagne"
    },
    "EDA.F": {
        "short_name": "EDAP TMS S.A. ADR EO -,13",
        "long_name": "EDAP TMS S.A.",
        "summary": "EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally-invasive medical devices for the treatment of urological diseases worldwide. It operates in two divisions, High Intensity Focused Ultrasound (HIFU) and Urological Devices and Services (UDS). The HIFU division develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications. This segment offers Ablatherm, an ultrasound guided robotic HIFU device for the treatment of organ-confined prostate cancer; Ablatherm Fusion that incorporates the company's proprietary fusion software, which merges MRI and ultrasound images; and the Focal One, a HIFU robotic device dedicated to the focal therapy of prostate cancer. It also provides disposables, and leasing and treatment related services; and maintenance services. The UDS division develops, markets, manufactures, and services medical devices for the minimally invasive diagnosis or treatment of urological disorders primarily urinary stones and other clinical indications. This segment offers Sonolith i-move, an extracorporeal shockwave lithotripter to small and mid-size hospitals; and Endo-UP platform, manages urinary stones, as well as Sonolith i-sys. It also leases lithotripters; sells disposables and spare parts; maintenance services; and distributes urodynamic products and urology lasers. The company markets and sells its products through its direct marketing, sales organization, and service platform, as well as through third-party distributors and agents. Its customers include public and private hospitals, urology clinics, and research institutions. The company was founded in 1979 and is headquartered in Lyon, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "France",
        "city": "Lyon"
    },
    "EDAP": {
        "short_name": "EDAP TMS S.A.",
        "long_name": "EDAP TMS S.A.",
        "summary": "EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally-invasive medical devices for the treatment of urological diseases worldwide. It operates in two divisions, High Intensity Focused Ultrasound (HIFU) and Urological Devices and Services (UDS). The HIFU division develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications. This segment offers Ablatherm, an ultrasound guided robotic HIFU device for the treatment of organ-confined prostate cancer; Ablatherm Fusion that incorporates the company's proprietary fusion software, which merges MRI and ultrasound images; and the Focal One, a HIFU robotic device dedicated to the focal therapy of prostate cancer. It also provides disposables, and leasing and treatment related services; and maintenance services. The UDS division develops, markets, manufactures, and services medical devices for the minimally invasive diagnosis or treatment of urological disorders primarily urinary stones and other clinical indications. This segment offers Sonolith i-move, an extracorporeal shockwave lithotripter to small and mid-size hospitals; and Endo-UP platform, manages urinary stones, as well as Sonolith i-sys. It also leases lithotripters; sells disposables and spare parts; maintenance services; and distributes urodynamic products and urology lasers. The company markets and sells its products through its direct marketing, sales organization, and service platform, as well as through third-party distributors and agents. Its customers include public and private hospitals, urology clinics, and research institutions. The company was founded in 1979 and is headquartered in Lyon, France.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "NMS",
        "market": "us_market",
        "country": "France",
        "city": "Lyon"
    },
    "EI.VI": {
        "short_name": "ESSILOR INTERNATIONAL SA",
        "long_name": "EssilorLuxottica Soci\u00e9t\u00e9 anonyme",
        "summary": "EssilorLuxottica Soci\u00c3\u00a9t\u00c3\u00a9 anonyme designs, manufactures, and distributes ophthalmic lenses, frames, and sunglasses in North America, Europe, and internationally. It operates in five segments: Wholesale, Retail, Lenses and Optical Instruments, Equipment, and Sunglasses & Readers. The Wholesale segment engages in the manufacture and wholesale distribution of luxury and sports eyewear. The Retail segment retails luxury and sports eyewear. The Lenses and Optical Instruments segment offers lenses and small equipment, including Varilux progressive lenses; Crizal antireflective, anti-smudge, and antistatic lenses; Transitions photochromic lenses; Eyezen lenses for users of computers, tablets, smartphones, and other connected devices; Xperio polarized sun lenses; and Nikon and Kodak corrective lens brands. It also provides lens edging and mounting instruments for opticians and prescription laboratories; and optometry instruments for eye care professionals, schools, occupational medicine centers, military, and other institutions. In addition, this segment develops solutions for online sales of optical products. The Equipment segment offers digital surfacing machines and lens coating machines to prescription laboratories, integrated optical chains, and lens manufacturers. The Sunglasses & Readers segment provides non-prescription sunglasses and reading glasses under the Foster Grant, Freedom Polarised, Gargoyles, Magnivision, Corinne McCormack, Monkey Monkey, Ryders Eyewear, SolarShield, and Suuna brands; Dockers, French Connection, Hello Kitty, Ironman, Karen Millen, Nine West, Reebok, and Disney brands; and Costa, Bolon, Molsion, and Prosun brands. It has a network of 449 prescription laboratories and edging-mounting facilities. The company was formerly known as Essilor International Soci\u00c3\u00a9t\u00c3\u00a9 Anonyme and changed its name to EssilorLuxottica Soci\u00c3\u00a9t\u00c3\u00a9 anonyme in October 2018. EssilorLuxottica Soci\u00c3\u00a9t\u00c3\u00a9 anonyme was founded in 1849 and is headquartered in Paris, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "VIE",
        "market": "at_market",
        "country": "France",
        "city": "Paris"
    },
    "EL.MI": {
        "short_name": "ESSILORLUXOTTICA",
        "long_name": "EssilorLuxottica Soci\u00e9t\u00e9 anonyme",
        "summary": "EssilorLuxottica Soci\u00c3\u00a9t\u00c3\u00a9 anonyme designs, manufactures, and distributes ophthalmic lenses, frames, and sunglasses in North America, Europe, and internationally. It operates in five segments: Wholesale, Retail, Lenses and Optical Instruments, Equipment, and Sunglasses & Readers. The Wholesale segment engages in the manufacture and wholesale distribution of luxury and sports eyewear. The Retail segment retails luxury and sports eyewear. The Lenses and Optical Instruments segment offers lenses and small equipment, including Varilux progressive lenses; Crizal antireflective, anti-smudge, and antistatic lenses; Transitions photochromic lenses; Eyezen lenses for users of computers, tablets, smartphones, and other connected devices; Xperio polarized sun lenses; and Nikon and Kodak corrective lens brands. It also provides lens edging and mounting instruments for opticians and prescription laboratories; and optometry instruments for eye care professionals, schools, occupational medicine centers, military, and other institutions. In addition, this segment develops solutions for online sales of optical products. The Equipment segment offers digital surfacing machines and lens coating machines to prescription laboratories, integrated optical chains, and lens manufacturers. The Sunglasses & Readers segment provides non-prescription sunglasses and reading glasses under the Foster Grant, Freedom Polarised, Gargoyles, Magnivision, Corinne McCormack, Monkey Monkey, Ryders Eyewear, SolarShield, and Suuna brands; Dockers, French Connection, Hello Kitty, Ironman, Karen Millen, Nine West, Reebok, and Disney brands; and Costa, Bolon, Molsion, and Prosun brands. It has a network of 449 prescription laboratories and edging-mounting facilities. The company was formerly known as Essilor International Soci\u00c3\u00a9t\u00c3\u00a9 Anonyme and changed its name to EssilorLuxottica Soci\u00c3\u00a9t\u00c3\u00a9 anonyme in October 2018. EssilorLuxottica Soci\u00c3\u00a9t\u00c3\u00a9 anonyme was founded in 1849 and is headquartered in Paris, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "MIL",
        "market": "it_market",
        "country": "France",
        "city": "Paris"
    },
    "EL.PA": {
        "short_name": "ESSILORLUXOTTICA",
        "long_name": "EssilorLuxottica Soci\u00e9t\u00e9 anonyme",
        "summary": "EssilorLuxottica Soci\u00c3\u00a9t\u00c3\u00a9 anonyme designs, manufactures, and distributes ophthalmic lenses, frames, and sunglasses in North America, Europe, and internationally. It operates in five segments: Wholesale, Retail, Lenses and Optical Instruments, Equipment, and Sunglasses & Readers. The Wholesale segment engages in the manufacture and wholesale distribution of luxury and sports eyewear. The Retail segment retails luxury and sports eyewear. The Lenses and Optical Instruments segment offers lenses and small equipment, including Varilux progressive lenses; Crizal antireflective, anti-smudge, and antistatic lenses; Transitions photochromic lenses; Eyezen lenses for users of computers, tablets, smartphones, and other connected devices; Xperio polarized sun lenses; and Nikon and Kodak corrective lens brands. It also provides lens edging and mounting instruments for opticians and prescription laboratories; and optometry instruments for eye care professionals, schools, occupational medicine centers, military, and other institutions. In addition, this segment develops solutions for online sales of optical products. The Equipment segment offers digital surfacing machines and lens coating machines to prescription laboratories, integrated optical chains, and lens manufacturers. The Sunglasses & Readers segment provides non-prescription sunglasses and reading glasses under the Foster Grant, Freedom Polarised, Gargoyles, Magnivision, Corinne McCormack, Monkey Monkey, Ryders Eyewear, SolarShield, and Suuna brands; Dockers, French Connection, Hello Kitty, Ironman, Karen Millen, Nine West, Reebok, and Disney brands; and Costa, Bolon, Molsion, and Prosun brands. It has a network of 449 prescription laboratories and edging-mounting facilities. The company was formerly known as Essilor International Soci\u00c3\u00a9t\u00c3\u00a9 Anonyme and changed its name to EssilorLuxottica Soci\u00c3\u00a9t\u00c3\u00a9 anonyme in October 2018. EssilorLuxottica Soci\u00c3\u00a9t\u00c3\u00a9 anonyme was founded in 1849 and is headquartered in Paris, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Paris"
    },
    "ELUN.MX": {
        "short_name": "ESSILORLUXOTTICA",
        "long_name": "EssilorLuxottica Soci\u00e9t\u00e9 anonyme",
        "summary": "EssilorLuxottica Soci\u00c3\u00a9t\u00c3\u00a9 anonyme designs, manufactures, and distributes ophthalmic lenses, frames, and sunglasses in North America, Europe, and internationally. It operates in five segments: Wholesale, Retail, Lenses and Optical Instruments, Equipment, and Sunglasses & Readers. The Wholesale segment engages in the manufacture and wholesale distribution of luxury and sports eyewear. The Retail segment retails luxury and sports eyewear. The Lenses and Optical Instruments segment offers lenses and small equipment, including Varilux progressive lenses; Crizal antireflective, anti-smudge, and antistatic lenses; Transitions photochromic lenses; Eyezen lenses for users of computers, tablets, smartphones, and other connected devices; Xperio polarized sun lenses; and Nikon and Kodak corrective lens brands. It also provides lens edging and mounting instruments for opticians and prescription laboratories; and optometry instruments for eye care professionals, schools, occupational medicine centers, military, and other institutions. In addition, this segment develops solutions for online sales of optical products. The Equipment segment offers digital surfacing machines and lens coating machines to prescription laboratories, integrated optical chains, and lens manufacturers. The Sunglasses & Readers segment provides non-prescription sunglasses and reading glasses under the Foster Grant, Freedom Polarised, Gargoyles, Magnivision, Corinne McCormack, Monkey Monkey, Ryders Eyewear, SolarShield, and Suuna brands; Dockers, French Connection, Hello Kitty, Ironman, Karen Millen, Nine West, Reebok, and Disney brands; and Costa, Bolon, Molsion, and Prosun brands. It has a network of 449 prescription laboratories and edging-mounting facilities. The company was formerly known as Essilor International Soci\u00c3\u00a9t\u00c3\u00a9 Anonyme and changed its name to EssilorLuxottica Soci\u00c3\u00a9t\u00c3\u00a9 anonyme in October 2018. EssilorLuxottica Soci\u00c3\u00a9t\u00c3\u00a9 anonyme was founded in 1849 and is headquartered in Paris, France.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "France",
        "city": "Paris"
    },
    "EOSI.PA": {
        "short_name": "EOS IMAGING",
        "long_name": "EOS imaging SA",
        "summary": "EOS imaging SA, together with its subsidiaries, develops, markets, and sells medical imaging devices for osteo-articular conditions and orthopedics, and related applications. It offers EOS, an imaging system that provides low dose, full body, and stereo-radiographic images of patient in a functional position; EOSedge, an X-ray system that provides images quality for patients; sterEOS, a 3D modeling workstation that analyzes frontal and lateral EOS images which are captured simultaneously and registered to generate precise, patient-specific, and 3D models of the spine and/or lower limbs from weight-bearing, low dose, or Micro Dose EOS exams; and EOSapps, an online 3D surgical planning solutions based on unbiased, weight-bearing EOS images, and an accurate 2D/3D patient-specific data set. The company also develops knee and hip surgery planning software, as well as manufactures patient-specific cutting guides for orthopedic surgeries. It sells its products in Europe, the Middle East, Africa, North America, the Asia-Pacific, and Latin America. The company was formerly known as biospace med and changed its name to EOS Imaging SA in 2010. EOS imaging SA was founded in 1989 and is headquartered in Paris, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Paris"
    },
    "ERYP": {
        "short_name": "Erytech Pharma S.A.",
        "long_name": "ERYTECH Pharma S.A.",
        "summary": "ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases. The company's lead product candidate is eryaspase, which is in Phase III clinical development for the treatment of second-line pancreatic cancer and in Phase II stage for the treatment of triple-negative breast cancer. It also engages in developing erymethionase, a preclinical product candidate that consists of methionine-gamma-lyase encapsulated in red blood cells to target methionine-dependent cancers. ERYTECH Pharma S.A. has research collaborations with the Fox Chase Cancer Center to advance the preclinical development of erymethionase for the treatment of homocystinuria; and Queen's University of Canada to advance the preclinical development of eryminase for the treatment of arginase-1-deficiency. The company was founded in 2004 and is headquartered in Lyon, France.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "France",
        "city": "Lyon"
    },
    "ERYP.PA": {
        "short_name": "ERYTECH PHARMA",
        "long_name": "ERYTECH Pharma S.A.",
        "summary": "ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases. The company's lead product candidate is eryaspase, which is in Phase III clinical development for the treatment of second-line pancreatic cancer and in Phase II stage for the treatment of triple-negative breast cancer. It also engages in developing erymethionase, a preclinical product candidate that consists of methionine-gamma-lyase encapsulated in red blood cells to target methionine-dependent cancers. ERYTECH Pharma S.A. has research collaborations with the Fox Chase Cancer Center to advance the preclinical development of erymethionase for the treatment of homocystinuria; and Queen's University of Canada to advance the preclinical development of eryminase for the treatment of arginase-1-deficiency. The company was founded in 2004 and is headquartered in Lyon, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Lyon"
    },
    "ESL.F": {
        "short_name": "ESSILORLUXO. INH. EO -,18",
        "long_name": "EssilorLuxottica Soci\u00e9t\u00e9 anonyme",
        "summary": "EssilorLuxottica Soci\u00c3\u00a9t\u00c3\u00a9 anonyme designs, manufactures, and distributes ophthalmic lenses, frames, and sunglasses in North America, Europe, and internationally. It operates in five segments: Wholesale, Retail, Lenses and Optical Instruments, Equipment, and Sunglasses & Readers. The Wholesale segment engages in the manufacture and wholesale distribution of luxury and sports eyewear. The Retail segment retails luxury and sports eyewear. The Lenses and Optical Instruments segment offers lenses and small equipment, including Varilux progressive lenses; Crizal antireflective, anti-smudge, and antistatic lenses; Transitions photochromic lenses; Eyezen lenses for users of computers, tablets, smartphones, and other connected devices; Xperio polarized sun lenses; and Nikon and Kodak corrective lens brands. It also provides lens edging and mounting instruments for opticians and prescription laboratories; and optometry instruments for eye care professionals, schools, occupational medicine centers, military, and other institutions. In addition, this segment develops solutions for online sales of optical products. The Equipment segment offers digital surfacing machines and lens coating machines to prescription laboratories, integrated optical chains, and lens manufacturers. The Sunglasses & Readers segment provides non-prescription sunglasses and reading glasses under the Foster Grant, Freedom Polarised, Gargoyles, Magnivision, Corinne McCormack, Monkey Monkey, Ryders Eyewear, SolarShield, and Suuna brands; Dockers, French Connection, Hello Kitty, Ironman, Karen Millen, Nine West, Reebok, and Disney brands; and Costa, Bolon, Molsion, and Prosun brands. It has a network of 449 prescription laboratories and edging-mounting facilities. The company was formerly known as Essilor International Soci\u00c3\u00a9t\u00c3\u00a9 Anonyme and changed its name to EssilorLuxottica Soci\u00c3\u00a9t\u00c3\u00a9 anonyme in October 2018. EssilorLuxottica Soci\u00c3\u00a9t\u00c3\u00a9 anonyme was founded in 1849 and is headquartered in Paris, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "France",
        "city": "Paris"
    },
    "ESLC.F": {
        "short_name": "ESSILORLUXOTTICA 1/2/O.N.",
        "long_name": "EssilorLuxottica Soci\u00e9t\u00e9 anonyme",
        "summary": "EssilorLuxottica Soci\u00c3\u00a9t\u00c3\u00a9 anonyme designs, manufactures, and distributes ophthalmic lenses, frames, and sunglasses in North America, Europe, and internationally. It operates in five segments: Wholesale, Retail, Lenses and Optical Instruments, Equipment, and Sunglasses & Readers. The Wholesale segment engages in the manufacture and wholesale distribution of luxury and sports eyewear. The Retail segment retails luxury and sports eyewear. The Lenses and Optical Instruments segment offers lenses and small equipment, including Varilux progressive lenses; Crizal antireflective, anti-smudge, and antistatic lenses; Transitions photochromic lenses; Eyezen lenses for users of computers, tablets, smartphones, and other connected devices; Xperio polarized sun lenses; and Nikon and Kodak corrective lens brands. It also provides lens edging and mounting instruments for opticians and prescription laboratories; and optometry instruments for eye care professionals, schools, occupational medicine centers, military, and other institutions. In addition, this segment develops solutions for online sales of optical products. The Equipment segment offers digital surfacing machines and lens coating machines to prescription laboratories, integrated optical chains, and lens manufacturers. The Sunglasses & Readers segment provides non-prescription sunglasses and reading glasses under the Foster Grant, Freedom Polarised, Gargoyles, Magnivision, Corinne McCormack, Monkey Monkey, Ryders Eyewear, SolarShield, and Suuna brands; Dockers, French Connection, Hello Kitty, Ironman, Karen Millen, Nine West, Reebok, and Disney brands; and Costa, Bolon, Molsion, and Prosun brands. It has a network of 449 prescription laboratories and edging-mounting facilities. The company was formerly known as Essilor International Soci\u00c3\u00a9t\u00c3\u00a9 Anonyme and changed its name to EssilorLuxottica Soci\u00c3\u00a9t\u00c3\u00a9 anonyme in October 2018. EssilorLuxottica Soci\u00c3\u00a9t\u00c3\u00a9 anonyme was founded in 1849 and is headquartered in Paris, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "France",
        "city": "Paris"
    },
    "ESLOF": {
        "short_name": "ESSILORLUXOTTICA",
        "long_name": "EssilorLuxottica Soci\u00e9t\u00e9 anonyme",
        "summary": "EssilorLuxottica Soci\u00c3\u00a9t\u00c3\u00a9 anonyme designs, manufactures, and distributes ophthalmic lenses, frames, and sunglasses in North America, Europe, and internationally. It operates in five segments: Wholesale, Retail, Lenses and Optical Instruments, Equipment, and Sunglasses & Readers. The Wholesale segment engages in the manufacture and wholesale distribution of luxury and sports eyewear. The Retail segment retails luxury and sports eyewear. The Lenses and Optical Instruments segment offers lenses and small equipment, including Varilux progressive lenses; Crizal antireflective, anti-smudge, and antistatic lenses; Transitions photochromic lenses; Eyezen lenses for users of computers, tablets, smartphones, and other connected devices; Xperio polarized sun lenses; and Nikon and Kodak corrective lens brands. It also provides lens edging and mounting instruments for opticians and prescription laboratories; and optometry instruments for eye care professionals, schools, occupational medicine centers, military, and other institutions. In addition, this segment develops solutions for online sales of optical products. The Equipment segment offers digital surfacing machines and lens coating machines to prescription laboratories, integrated optical chains, and lens manufacturers. The Sunglasses & Readers segment provides non-prescription sunglasses and reading glasses under the Foster Grant, Freedom Polarised, Gargoyles, Magnivision, Corinne McCormack, Monkey Monkey, Ryders Eyewear, SolarShield, and Suuna brands; Dockers, French Connection, Hello Kitty, Ironman, Karen Millen, Nine West, Reebok, and Disney brands; and Costa, Bolon, Molsion, and Prosun brands. It has a network of 449 prescription laboratories and edging-mounting facilities. The company was formerly known as Essilor International Soci\u00c3\u00a9t\u00c3\u00a9 Anonyme and changed its name to EssilorLuxottica Soci\u00c3\u00a9t\u00c3\u00a9 anonyme in October 2018. EssilorLuxottica Soci\u00c3\u00a9t\u00c3\u00a9 anonyme was founded in 1849 and is headquartered in Paris, France.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "PNK",
        "market": "us_market",
        "country": "France",
        "city": "Paris"
    },
    "ESLOY": {
        "short_name": "ESSILORLUXOTTICA",
        "long_name": "EssilorLuxottica Soci\u00e9t\u00e9 anonyme",
        "summary": "EssilorLuxottica Soci\u00c3\u00a9t\u00c3\u00a9 anonyme designs, manufactures, and distributes ophthalmic lenses, frames, and sunglasses in North America, Europe, and internationally. It operates in five segments: Wholesale, Retail, Lenses and Optical Instruments, Equipment, and Sunglasses & Readers. The Wholesale segment engages in the manufacture and wholesale distribution of luxury and sports eyewear. The Retail segment retails luxury and sports eyewear. The Lenses and Optical Instruments segment offers lenses and small equipment, including Varilux progressive lenses; Crizal antireflective, anti-smudge, and antistatic lenses; Transitions photochromic lenses; Eyezen lenses for users of computers, tablets, smartphones, and other connected devices; Xperio polarized sun lenses; and Nikon and Kodak corrective lens brands. It also provides lens edging and mounting instruments for opticians and prescription laboratories; and optometry instruments for eye care professionals, schools, occupational medicine centers, military, and other institutions. In addition, this segment develops solutions for online sales of optical products. The Equipment segment offers digital surfacing machines and lens coating machines to prescription laboratories, integrated optical chains, and lens manufacturers. The Sunglasses & Readers segment provides non-prescription sunglasses and reading glasses under the Foster Grant, Freedom Polarised, Gargoyles, Magnivision, Corinne McCormack, Monkey Monkey, Ryders Eyewear, SolarShield, and Suuna brands; Dockers, French Connection, Hello Kitty, Ironman, Karen Millen, Nine West, Reebok, and Disney brands; and Costa, Bolon, Molsion, and Prosun brands. It has a network of 449 prescription laboratories and edging-mounting facilities. The company was formerly known as Essilor International Soci\u00c3\u00a9t\u00c3\u00a9 Anonyme and changed its name to EssilorLuxottica Soci\u00c3\u00a9t\u00c3\u00a9 anonyme in October 2018. EssilorLuxottica Soci\u00c3\u00a9t\u00c3\u00a9 anonyme was founded in 1849 and is headquartered in Paris, France.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "PNK",
        "market": "us_market",
        "country": "France",
        "city": "Paris"
    },
    "EYWN.F": {
        "short_name": "BIOMERIEUX (P.S.)  O.N.",
        "long_name": "bioM\u00e9rieux S.A.",
        "summary": "bioM\u00c3\u00a9rieux S.A. provides vitro diagnostic solutions systems for private and hospital laboratories, primarily for the diagnosis of infectious diseases. The company offers microbiology technology that identifies microorganism present in biological samples; and immunoassays technology based on antigen-antibody reaction, detects and measures infectious agents, such as bacteria, viruses, and parasites, as well as pathological markers. It also provides molecular biology for the detection of genetic sequences of deoxyribonucleic acid or ribonucleic acid; and companion diagnostic test, as well as services for clinical and industrial laboratories. The company was formerly known as B-D M\u00c3\u00a9rieux. bioM\u00c3\u00a9rieux S.A. was founded in 1963 and is headquartered in Marcy l'Etoile, France. bioM\u00c3\u00a9rieux S.A. is a subsidiary of Institut M\u00c3\u00a9rieux SA.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "France",
        "city": "Marcy l'\u00c3\u0089toile"
    },
    "FALG.PA": {
        "short_name": "FERMENTALG",
        "long_name": "Fermentalg Soci\u00e9t\u00e9 Anonyme",
        "summary": "Fermentalg Soci\u00c3\u00a9t\u00c3\u00a9 Anonyme develops, produces, and sells active ingredients extracted from microalgae for the food, health, and nutrition sectors in France and internationally. It offers DHA ORIGINS, a plant based DHA oil; PROTEALG, a vegetable protein; BLUE ORIGIN, a natural color substitutes for human health and nutrition; and Carbon sinks to capture CO2 in urban and industrial environments. The company was founded in 2009 and is based in Libourne, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Libourne"
    },
    "G061.F": {
        "short_name": "GENKYOTEX S.A. EO 1,-",
        "long_name": "Genkyotex SA",
        "summary": "Genkyotex SA, a biopharmaceutical company, develops oral small molecule NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit NOX enzymes amplifying various disease processes, such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company's lead product candidate is GKT831, a NOX1 and NOX4 inhibitor, which is evaluated in a Phase II clinical trial in primary biliary cholangitis a fibrotic orphan disease and in an investigator-initiated Phase II clinical trial in type 1 diabetes and kidney disease. Its preclinical stage product candidate is GKT771, a NOX1 inhibitor targeting various pathways in pain processing and inflammation. Genkyotex SA has a license agreement with Serum Institute of India Ltd. for GTL003, an antigen for use in the development of acellular multivalent combination vaccines against a variety of infectious diseases. The company was founded in 2006 and is headquartered in Lab\u00c3\u00a8ge, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "France",
        "city": "Lab\u00c3\u00a8ge"
    },
    "G49N.F": {
        "short_name": "GENSIGHT BIOLOG. EO -,025",
        "long_name": "GenSight Biologics S.A.",
        "summary": "GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery and development of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial target sequence and optogenetics technology platforms. Its lead product candidates include GS010, an AAV2 based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by mutation of the ND4 gene; and GS030 that is in Phase I/II trial for the treatment of retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. The company is also developing products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. GenSight Biologics S.A. was founded in 2012 and is headquartered in Paris, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "France",
        "city": "Paris"
    },
    "GBT.PA": {
        "short_name": "GUERBET",
        "long_name": "Guerbet SA",
        "summary": "Guerbet SA engages in the research, development, production, and sale of contrast media products, delivery systems, medical devices, and related solutions worldwide. Its products for the CT and Cath Lab examinations include Optiray, a low osmolar contrast medium; Xenetix, a low-osmolar iodinated agent; Telebrix, a high osmolar contrast medium; Conray and MD high osmolar contrast medium products; Hexabrix, an ionic low osmolar contrast medium agent; and Micropaque/ Microtrast, a diagnostic imaging interconnected solution. The company's products for the magnetic resonance imaging examinations comprise Dotarem, a non-specific gadolinium-based contrast medium; Artirem products; and Optimark, a contrast medium. In addition, it provides products for interventional imaging, including Lipiodol ethyl esters of iodinated fatty acids of poppy seed oil; Vectorio, a classic transarterial chemoembolization mixing and injection system; Patent Blue V, an injectable medium; and SeQure and DraKon, a microcatheters. Further, the company offers delivery systems and services comprising injectors; consumables for various types of injectors; Contrast&Care, a patient data management software; Dose&Care, an operational solution for monitoring patient exposure to ionizing radiation; and Hydra Vision, a digital imaging system for urological, gastroenterological, gynecological treatment, and planning and diagnostic procedures. The company distributes its products directly, as well as through distributors and license-holders primarily to hospitals, clinics, radiology centers, purchasing pools, and wholesalers. Guerbet SA was founded in 1926 and is headquartered in Villepinte, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Villepinte"
    },
    "GD6.F": {
        "short_name": "RAMSAY GEN.D.S.INH.EO-,75",
        "long_name": "Ramsay G\u00e9n\u00e9rale de Sant\u00e9 SA",
        "summary": "Ramsay G\u00c3\u00a9n\u00c3\u00a9rale de Sant\u00c3\u00a9 SA operates hospitals in France. Its hospitals offer a range of services in the areas of anesthesia, oncology, cardiology, dermatology, gastroenterology, gynecology, maternity, nephrology, neurosurgery, obesity, ophthalmology, orthopedics, stomatology, pneumonology, psychiatry, radiology, and urology, as well as heart, hand, digestive, thoracic, vascular, and endovascular surgeries. The company was formerly known as G\u00c3\u00a9n\u00c3\u00a9rale de Sant\u00c3\u00a9 SA and changed its name to Ramsay G\u00c3\u00a9n\u00c3\u00a9rale de Sant\u00c3\u00a9 SA in December 2015. Ramsay G\u00c3\u00a9n\u00c3\u00a9rale de Sant\u00c3\u00a9 SA was founded in 1987 and is based in Paris, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "France",
        "city": "Paris"
    },
    "GDS.PA": {
        "short_name": "RAMSAY GEN SANTE",
        "long_name": "Ramsay G\u00e9n\u00e9rale de Sant\u00e9 SA",
        "summary": "Ramsay G\u00c3\u00a9n\u00c3\u00a9rale de Sant\u00c3\u00a9 SA operates hospitals in France. Its hospitals offer a range of services in the areas of anesthesia, oncology, cardiology, dermatology, gastroenterology, gynecology, maternity, nephrology, neurosurgery, obesity, ophthalmology, orthopedics, stomatology, pneumonology, psychiatry, radiology, and urology, as well as heart, hand, digestive, thoracic, vascular, and endovascular surgeries. The company was formerly known as G\u00c3\u00a9n\u00c3\u00a9rale de Sant\u00c3\u00a9 SA and changed its name to Ramsay G\u00c3\u00a9n\u00c3\u00a9rale de Sant\u00c3\u00a9 SA in December 2015. Ramsay G\u00c3\u00a9n\u00c3\u00a9rale de Sant\u00c3\u00a9 SA was founded in 1987 and is based in Paris, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Paris"
    },
    "GKTX.PA": {
        "short_name": "GENKYOTEX",
        "long_name": "Genkyotex SA",
        "summary": "Genkyotex SA, a biopharmaceutical company, develops oral small molecule NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit NOX enzymes amplifying various disease processes, such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company's lead product candidate is GKT831, a NOX1 and NOX4 inhibitor, which is evaluated in a Phase II clinical trial in primary biliary cholangitis a fibrotic orphan disease and in an investigator-initiated Phase II clinical trial in type 1 diabetes and kidney disease. Its preclinical stage product candidate is GKT771, a NOX1 inhibitor targeting various pathways in pain processing and inflammation. Genkyotex SA has a license agreement with Serum Institute of India Ltd. for GTL003, an antigen for use in the development of acellular multivalent combination vaccines against a variety of infectious diseases. The company was founded in 2006 and is headquartered in Lab\u00c3\u00a8ge, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Lab\u00c3\u00a8ge"
    },
    "GNFT": {
        "short_name": "GENFIT S.A.",
        "long_name": "Genfit SA",
        "summary": "Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, autoimmune, and fibrotic diseases affecting primarily the liver and gastroenterology. The company's lead products include Elafibranor, which is in pivotal Phase III clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as completed Phase II clinical trial to treat patients with primary biliary cholangitis; and Nitazoxanide that is in Phase II proof-of-concept clinical trial for the treatment of NASH-induced significant or severe fibrosis. It is also developing in-vitro diagnostic tests for the identification of patients with NASH; NIS4 for identifying patients with NASH and fibrosis; and TGFTX1 preclinical program for treating psoriasis or respiratory conditions, such as neutrophilic asthma, chronic obstructive pulmonary disease (COPD), and the asthma-COPD overlap syndrome. Genfit SA was founded in 1999 and is headquartered in Loos, France.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "France",
        "city": "Loos"
    },
    "GNFT.PA": {
        "short_name": "GENFIT",
        "long_name": "Genfit SA",
        "summary": "Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, autoimmune, and fibrotic diseases affecting primarily the liver and gastroenterology. The company's lead products include Elafibranor, which is in pivotal Phase III clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as completed Phase II clinical trial to treat patients with primary biliary cholangitis; and Nitazoxanide that is in Phase II proof-of-concept clinical trial for the treatment of NASH-induced significant or severe fibrosis. It is also developing in-vitro diagnostic tests for the identification of patients with NASH; NIS4 for identifying patients with NASH and fibrosis; and TGFTX1 preclinical program for treating psoriasis or respiratory conditions, such as neutrophilic asthma, chronic obstructive pulmonary disease (COPD), and the asthma-COPD overlap syndrome. Genfit SA was founded in 1999 and is headquartered in Loos, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Loos"
    },
    "GNFTF": {
        "short_name": "GENFIT",
        "long_name": "Genfit SA",
        "summary": "Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, autoimmune, and fibrotic diseases affecting primarily the liver and gastroenterology. The company's lead products include Elafibranor, which is in pivotal Phase III clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as completed Phase II clinical trial to treat patients with primary biliary cholangitis; and Nitazoxanide that is in Phase II proof-of-concept clinical trial for the treatment of NASH-induced significant or severe fibrosis. It is also developing in-vitro diagnostic tests for the identification of patients with NASH; NIS4 for identifying patients with NASH and fibrosis; and TGFTX1 preclinical program for treating psoriasis or respiratory conditions, such as neutrophilic asthma, chronic obstructive pulmonary disease (COPD), and the asthma-COPD overlap syndrome. Genfit SA was founded in 1999 and is headquartered in Loos, France.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "France",
        "city": "Loos"
    },
    "I7G.F": {
        "short_name": "IPSEN S.A. PORT.  EO 1",
        "long_name": "Ipsen S.A.",
        "summary": "Ipsen S.A. operates as a biopharmaceutical company worldwide. It operates in two segments, Specialty Care and Consumer Healthcare. The company offers drugs in the areas of oncology, neuroscience, pituitary pathologies and growth disorders, gastrointestinal disorders, neurodegenerative pathologies, and rheumatology. Its products include Somatuline for neuroendocrine tumors and acromegaly; Cabometyx to treat renal cell and second-line hepatocellular carcinoma; Onivyde for metastatic pancreatic cancer; Decapeptyl to treat advanced metastatic prostate cancer, uterine fibroids, precocious puberty, endometriosis, female sterility, and early stage breast cancer; and Dysport for motor muscular disorders and medical aesthetics. The company also provides NutropinAq to treat growth failure in children due to growth hormone deficiency, turner syndrome, or chronic renal failure, as well as GH deficiency in adults; and Increlex for long-term treatment of growth failure in children and adolescents. In addition, it offers Smecta for the treatment of chronic and acute diarrhea, and pain linked to oesogastroduodenal conditions and colic; Forlax for constipation; and Fortrans/Eziclen for intestinal cleaning; Etiasa for inflammatory bowel diseases; and Tanakan to treat mild cognitive impairment related to age, pathophysiological deficiencies, vertigo, retinal deficits, acute or chronic hearing impairment, and tinnitus. Further, the company provides Adenuric for chronic hyperuricaemia; Prontalgine, an analgesic to treat moderate to severe pain; Buscopan, an antispasmodic; Suppositoria Glycerini, a laxative; and Mucothiol and Mucodyne, which are expectorants for cough and flu. The company has collaboration agreements with Arix Bioscience plc; The University of Texas MD Anderson Cancer Center; and Exelixis and Roche. Ipsen S.A. was founded in 1929 and is headquartered in Boulogne-Billancourt, France. Ipsen S.A. is a subsidiary of Mayroy S.A.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers\u2014Specialty & Generic",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "France",
        "city": "Boulogne-Billancourt"
    },
    "IDD.F": {
        "short_name": "INNATE PHARMA  EO -,05",
        "long_name": "Innate Pharma S.A.",
        "summary": "Innate Pharma S.A., a biotechnology company, discovers and develops therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Monalizumab, an immune checkpoint inhibitor that is in Phase II clinical trial to treat advanced solid tumors comprising colorectal cancer, as well as head and neck cancer; Anti-Siglec-9, checkpoint inhibitor program, which is in preclinical stage for immuno-oncology; Lumoxiti (moxetumomab pasudotox-tdfk), a tumor antigen targeting solution for the treatment of hairy cell leukemia; and Lacutamab (IPH4102), an anti-KIR3DL2 humanized cytotoxicity-inducing antibody, which is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma. Its products also include IPH61, a bispecific NK cell engager, a preclinical solution for the generation and evaluation of up to two bispecific NK cell engagers; IPH43, a program that is in preclinical trial to develop anti-MICA/B therapeutic antibody in oncology; Avdoralimab/IPH5401, a therapeutic antibody, which is in Phase II clinical trial that binds and blocks C5a receptors expressed on subsets of myeloid-derived suppressor cells and neutrophils; IPH5201, a blocking antibody that is in Phase I clinical trial targeting the CD39 immunosuppressive pathway; and IPH5301, a CD-73-blocking antibody that is in preclinical trial for restoring a pro-inflammatory microenvironment. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, and Sanofi; and co-development and license agreement with MedImmune. The company was founded in 1999 and is headquartered in Marseille, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "France",
        "city": "Marseille"
    },
    "IDDA.MU": {
        "short_name": "INNATE PHARMA SP.ADR/1",
        "long_name": "Innate Pharma S.A.",
        "summary": "Innate Pharma S.A., a biotechnology company, discovers and develops therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Monalizumab, an immune checkpoint inhibitor that is in Phase II clinical trial to treat advanced solid tumors comprising colorectal cancer, as well as head and neck cancer; Anti-Siglec-9, checkpoint inhibitor program, which is in preclinical stage for immuno-oncology; Lumoxiti (moxetumomab pasudotox-tdfk), a tumor antigen targeting solution for the treatment of hairy cell leukemia; and Lacutamab (IPH4102), an anti-KIR3DL2 humanized cytotoxicity-inducing antibody, which is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma. Its products also include IPH61, a bispecific NK cell engager, a preclinical solution for the generation and evaluation of up to two bispecific NK cell engagers; IPH43, a program that is in preclinical trial to develop anti-MICA/B therapeutic antibody in oncology; Avdoralimab/IPH5401, a therapeutic antibody, which is in Phase II clinical trial that binds and blocks C5a receptors expressed on subsets of myeloid-derived suppressor cells and neutrophils; IPH5201, a blocking antibody that is in Phase I clinical trial targeting the CD39 immunosuppressive pathway; and IPH5301, a CD-73-blocking antibody that is in preclinical trial for restoring a pro-inflammatory microenvironment. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, and Sanofi; and co-development and license agreement with MedImmune. The company was founded in 1999 and is headquartered in Marseille, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MUN",
        "market": "dr_market",
        "country": "France",
        "city": "Marseille"
    },
    "IM11.F": {
        "short_name": "IMPLANET SA  EO 0,10",
        "long_name": "Implanet S.A.",
        "summary": "Implanet S.A., together with its subsidiaries, designs, manufactures, and sells implants for orthopedic surgery in France, the United States, Brazil, and internationally. The company offers spinal, arthroscopy, and knee products. Its products include Jazz, Jazz Passer, Jazz Cap SP, Jazz Lock, Jazz Claw, Jazz Standalone, Jazz Frame, and Jazz Screw systems for posterior fixation. The company also offers knee prostheses, such as Madison for conventional surgical techniques. Implanet S.A. was founded in 2006 and is based in Martillac, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "France",
        "city": "Martillac"
    },
    "IMPZY": {
        "short_name": "IMPLANET",
        "long_name": "Implanet S.A.",
        "summary": "Implanet S.A., together with its subsidiaries, designs, manufactures, and sells implants for orthopedic surgery in France, the United States, Brazil, and internationally. The company offers spinal, arthroscopy, and knee products. Its products include Jazz, Jazz Passer, Jazz Cap SP, Jazz Lock, Jazz Claw, Jazz Standalone, Jazz Frame, and Jazz Screw systems for posterior fixation. The company also offers knee prostheses, such as Madison for conventional surgical techniques. Implanet S.A. was founded in 2006 and is based in Martillac, France.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "France",
        "city": "Martillac"
    },
    "INRLF": {
        "short_name": "VALNEVA SE",
        "long_name": "Valneva SE",
        "summary": "Valneva SE, a specialty vaccine company, engages in developing and commercializing vaccines for infectious diseases with unmet needs. Its portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT indicated for the prevention of Japanese encephalitis; and DUKORAL indicated for the prevention of cholera and in some countries prevention of diarrhea caused by ETEC. The company has various vaccines in development, including a vaccine against Lyme disease and single-shot vaccine against chikungunya. It has operations in Austria, Canada, France, Sweden, the United Kingdom, and the United States. The company has collaboration with Dynavax Technologies Corporation to advance vaccine development for COVID-19. Valneva SE was incorporated in 1999 and is headquartered in Nantes, France.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "France",
        "city": "Nantes"
    },
    "IPH.PA": {
        "short_name": "INNATE PHARMA",
        "long_name": "Innate Pharma S.A.",
        "summary": "Innate Pharma S.A., a biotechnology company, discovers and develops therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Monalizumab, an immune checkpoint inhibitor that is in Phase II clinical trial to treat advanced solid tumors comprising colorectal cancer, as well as head and neck cancer; Anti-Siglec-9, checkpoint inhibitor program, which is in preclinical stage for immuno-oncology; Lumoxiti (moxetumomab pasudotox-tdfk), a tumor antigen targeting solution for the treatment of hairy cell leukemia; and Lacutamab (IPH4102), an anti-KIR3DL2 humanized cytotoxicity-inducing antibody, which is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma. Its products also include IPH61, a bispecific NK cell engager, a preclinical solution for the generation and evaluation of up to two bispecific NK cell engagers; IPH43, a program that is in preclinical trial to develop anti-MICA/B therapeutic antibody in oncology; Avdoralimab/IPH5401, a therapeutic antibody, which is in Phase II clinical trial that binds and blocks C5a receptors expressed on subsets of myeloid-derived suppressor cells and neutrophils; IPH5201, a blocking antibody that is in Phase I clinical trial targeting the CD39 immunosuppressive pathway; and IPH5301, a CD-73-blocking antibody that is in preclinical trial for restoring a pro-inflammatory microenvironment. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, and Sanofi; and co-development and license agreement with MedImmune. The company was founded in 1999 and is headquartered in Marseille, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Marseille"
    },
    "IPHA": {
        "short_name": "Innate Pharma S.A.",
        "long_name": "Innate Pharma S.A.",
        "summary": "Innate Pharma S.A., a biotechnology company, discovers and develops therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Monalizumab, an immune checkpoint inhibitor that is in Phase II clinical trial to treat advanced solid tumors comprising colorectal cancer, as well as head and neck cancer; Anti-Siglec-9, checkpoint inhibitor program, which is in preclinical stage for immuno-oncology; Lumoxiti (moxetumomab pasudotox-tdfk), a tumor antigen targeting solution for the treatment of hairy cell leukemia; and Lacutamab (IPH4102), an anti-KIR3DL2 humanized cytotoxicity-inducing antibody, which is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma. Its products also include IPH61, a bispecific NK cell engager, a preclinical solution for the generation and evaluation of up to two bispecific NK cell engagers; IPH43, a program that is in preclinical trial to develop anti-MICA/B therapeutic antibody in oncology; Avdoralimab/IPH5401, a therapeutic antibody, which is in Phase II clinical trial that binds and blocks C5a receptors expressed on subsets of myeloid-derived suppressor cells and neutrophils; IPH5201, a blocking antibody that is in Phase I clinical trial targeting the CD39 immunosuppressive pathway; and IPH5301, a CD-73-blocking antibody that is in preclinical trial for restoring a pro-inflammatory microenvironment. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, and Sanofi; and co-development and license agreement with MedImmune. The company was founded in 1999 and is headquartered in Marseille, France.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "France",
        "city": "Marseille"
    },
    "IPHYF": {
        "short_name": "INNATE PHARMA",
        "long_name": "Innate Pharma S.A.",
        "summary": "Innate Pharma S.A., a biotechnology company, discovers and develops therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Monalizumab, an immune checkpoint inhibitor that is in Phase II clinical trial to treat advanced solid tumors comprising colorectal cancer, as well as head and neck cancer; Anti-Siglec-9, checkpoint inhibitor program, which is in preclinical stage for immuno-oncology; Lumoxiti (moxetumomab pasudotox-tdfk), a tumor antigen targeting solution for the treatment of hairy cell leukemia; and Lacutamab (IPH4102), an anti-KIR3DL2 humanized cytotoxicity-inducing antibody, which is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma. Its products also include IPH61, a bispecific NK cell engager, a preclinical solution for the generation and evaluation of up to two bispecific NK cell engagers; IPH43, a program that is in preclinical trial to develop anti-MICA/B therapeutic antibody in oncology; Avdoralimab/IPH5401, a therapeutic antibody, which is in Phase II clinical trial that binds and blocks C5a receptors expressed on subsets of myeloid-derived suppressor cells and neutrophils; IPH5201, a blocking antibody that is in Phase I clinical trial targeting the CD39 immunosuppressive pathway; and IPH5301, a CD-73-blocking antibody that is in preclinical trial for restoring a pro-inflammatory microenvironment. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, and Sanofi; and co-development and license agreement with MedImmune. The company was founded in 1999 and is headquartered in Marseille, France.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "France",
        "city": "Marseille"
    },
    "IPN.PA": {
        "short_name": "IPSEN",
        "long_name": "Ipsen S.A.",
        "summary": "Ipsen S.A. operates as a biopharmaceutical company worldwide. It operates in two segments, Specialty Care and Consumer Healthcare. The company offers drugs in the areas of oncology, neuroscience, pituitary pathologies and growth disorders, gastrointestinal disorders, neurodegenerative pathologies, and rheumatology. Its products include Somatuline for neuroendocrine tumors and acromegaly; Cabometyx to treat renal cell and second-line hepatocellular carcinoma; Onivyde for metastatic pancreatic cancer; Decapeptyl to treat advanced metastatic prostate cancer, uterine fibroids, precocious puberty, endometriosis, female sterility, and early stage breast cancer; and Dysport for motor muscular disorders and medical aesthetics. The company also provides NutropinAq to treat growth failure in children due to growth hormone deficiency, turner syndrome, or chronic renal failure, as well as GH deficiency in adults; and Increlex for long-term treatment of growth failure in children and adolescents. In addition, it offers Smecta for the treatment of chronic and acute diarrhea, and pain linked to oesogastroduodenal conditions and colic; Forlax for constipation; and Fortrans/Eziclen for intestinal cleaning; Etiasa for inflammatory bowel diseases; and Tanakan to treat mild cognitive impairment related to age, pathophysiological deficiencies, vertigo, retinal deficits, acute or chronic hearing impairment, and tinnitus. Further, the company provides Adenuric for chronic hyperuricaemia; Prontalgine, an analgesic to treat moderate to severe pain; Buscopan, an antispasmodic; Suppositoria Glycerini, a laxative; and Mucothiol and Mucodyne, which are expectorants for cough and flu. The company has collaboration agreements with Arix Bioscience plc; The University of Texas MD Anderson Cancer Center; and Exelixis and Roche. Ipsen S.A. was founded in 1929 and is headquartered in Boulogne-Billancourt, France. Ipsen S.A. is a subsidiary of Mayroy S.A.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers\u2014Specialty & Generic",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Boulogne-Billancourt"
    },
    "IPN.VI": {
        "short_name": "IPSEN",
        "long_name": "Ipsen S.A.",
        "summary": "Ipsen S.A. operates as a biopharmaceutical company worldwide. It operates in two segments, Specialty Care and Consumer Healthcare. The company offers drugs in the areas of oncology, neuroscience, pituitary pathologies and growth disorders, gastrointestinal disorders, neurodegenerative pathologies, and rheumatology. Its products include Somatuline for neuroendocrine tumors and acromegaly; Cabometyx to treat renal cell and second-line hepatocellular carcinoma; Onivyde for metastatic pancreatic cancer; Decapeptyl to treat advanced metastatic prostate cancer, uterine fibroids, precocious puberty, endometriosis, female sterility, and early stage breast cancer; and Dysport for motor muscular disorders and medical aesthetics. The company also provides NutropinAq to treat growth failure in children due to growth hormone deficiency, turner syndrome, or chronic renal failure, as well as GH deficiency in adults; and Increlex for long-term treatment of growth failure in children and adolescents. In addition, it offers Smecta for the treatment of chronic and acute diarrhea, and pain linked to oesogastroduodenal conditions and colic; Forlax for constipation; and Fortrans/Eziclen for intestinal cleaning; Etiasa for inflammatory bowel diseases; and Tanakan to treat mild cognitive impairment related to age, pathophysiological deficiencies, vertigo, retinal deficits, acute or chronic hearing impairment, and tinnitus. Further, the company provides Adenuric for chronic hyperuricaemia; Prontalgine, an analgesic to treat moderate to severe pain; Buscopan, an antispasmodic; Suppositoria Glycerini, a laxative; and Mucothiol and Mucodyne, which are expectorants for cough and flu. The company has collaboration agreements with Arix Bioscience plc; The University of Texas MD Anderson Cancer Center; and Exelixis and Roche. Ipsen S.A. was founded in 1929 and is headquartered in Boulogne-Billancourt, France. Ipsen S.A. is a subsidiary of Mayroy S.A.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers\u2014Specialty & Generic",
        "exchange": "VIE",
        "market": "at_market",
        "country": "France",
        "city": "Boulogne-Billancourt"
    },
    "IPSEY": {
        "short_name": "IPSEN SA",
        "long_name": "Ipsen S.A.",
        "summary": "Ipsen S.A. operates as a biopharmaceutical company worldwide. It operates in two segments, Specialty Care and Consumer Healthcare. The company offers drugs in the areas of oncology, neuroscience, pituitary pathologies and growth disorders, gastrointestinal disorders, neurodegenerative pathologies, and rheumatology. Its products include Somatuline for neuroendocrine tumors and acromegaly; Cabometyx to treat renal cell and second-line hepatocellular carcinoma; Onivyde for metastatic pancreatic cancer; Decapeptyl to treat advanced metastatic prostate cancer, uterine fibroids, precocious puberty, endometriosis, female sterility, and early stage breast cancer; and Dysport for motor muscular disorders and medical aesthetics. The company also provides NutropinAq to treat growth failure in children due to growth hormone deficiency, turner syndrome, or chronic renal failure, as well as GH deficiency in adults; and Increlex for long-term treatment of growth failure in children and adolescents. In addition, it offers Smecta for the treatment of chronic and acute diarrhea, and pain linked to oesogastroduodenal conditions and colic; Forlax for constipation; and Fortrans/Eziclen for intestinal cleaning; Etiasa for inflammatory bowel diseases; and Tanakan to treat mild cognitive impairment related to age, pathophysiological deficiencies, vertigo, retinal deficits, acute or chronic hearing impairment, and tinnitus. Further, the company provides Adenuric for chronic hyperuricaemia; Prontalgine, an analgesic to treat moderate to severe pain; Buscopan, an antispasmodic; Suppositoria Glycerini, a laxative; and Mucothiol and Mucodyne, which are expectorants for cough and flu. The company has collaboration agreements with Arix Bioscience plc; The University of Texas MD Anderson Cancer Center; and Exelixis and Roche. Ipsen S.A. was founded in 1929 and is headquartered in Boulogne-Billancourt, France. Ipsen S.A. is a subsidiary of Mayroy S.A.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers\u2014Specialty & Generic",
        "exchange": "PNK",
        "market": "us_market",
        "country": "France",
        "city": "Boulogne-Billancourt"
    },
    "IVA": {
        "short_name": "Inventiva S.A. - American Depos",
        "long_name": "Inventiva S.A.",
        "summary": "Inventiva S.A., a biopharmaceutical company, develops drugs for the treatment of fibrotic, cancer, and orphan diseases. Its lead product candidate is Lanifibranor that is in Phase IIb clinical trial to treat nonalcoholic steatohepatitis and systemic sclerosis. The company also develops Odiparcil, which is in Phase IIa clinical trial primarily for the treatment of mucopolysaccharidosis type VI disease; YAP-TEAD that is in preclinical stage to treat malignant mesothelioma and lung cancer; NSD2 for the treatment of multiple myeloma; and EPICURE for immuno-oncology treatment. It has partnership collaborations with the Institut Curie in the field of oncology; AbbVie for developing ROR? project that is used for the treatment of autoimmune diseases, as well as other projects relating to fibrosis; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "France",
        "city": "Daix"
    },
    "IVA.PA": {
        "short_name": "INVENTIVA",
        "long_name": "Inventiva S.A.",
        "summary": "Inventiva S.A., a biopharmaceutical company, develops drugs for the treatment of fibrotic, cancer, and orphan diseases. Its lead product candidate is Lanifibranor that is in Phase IIb clinical trial to treat nonalcoholic steatohepatitis and systemic sclerosis. The company also develops Odiparcil, which is in Phase IIa clinical trial primarily for the treatment of mucopolysaccharidosis type VI disease; YAP-TEAD that is in preclinical stage to treat malignant mesothelioma and lung cancer; NSD2 for the treatment of multiple myeloma; and EPICURE for immuno-oncology treatment. It has partnership collaborations with the Institut Curie in the field of oncology; AbbVie for developing ROR? project that is used for the treatment of autoimmune diseases, as well as other projects relating to fibrosis; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Daix"
    },
    "JEH.F": {
        "short_name": "GENOWAY S.A. INH.  EO-,60",
        "long_name": "genOway S.A.",
        "summary": "genOway S.A., a biotechnology company, engages in the development and sale of custom genetically-modified mouse, rat, and cellular models worldwide. The company provides technological solutions for transgenesis and model design. It produces custom mouse models, such as knockout (KO) and knockin (KI) mouse models; custom rat models; custom cell models; catalog models; and phenotyping for in vivo or in vitro studies. The company also provides patented homologous recombination technology for the generation of genetically modified rodent models; CRISPR/Cas9 nuclease systems for the KO and KI model creation; and FLEx, an inducible point mutation technology that allows scientists to induce the expression of a mutated gene or a reporter gene during the lifetime of the animal model. In addition, it offers tetracycline on/off systems to control gene expression; and internal ribosome entry site technology to generate multigenic-based disease models, reporter models, cell lineage tracking models, and tissue-specific Cre driver lines, as well as to monitor cell expression patterns in KO models. Further, the company provides recombinase-mediated cassette exchange technology to enable the swapping of genomic regions; and Quick Knockin technology, such as Rosa26, Hprt, and AAVS1. It serves pharmaceutical and life science companies, and academic institutes. genOway S.A. has a strategic alliance with Merck to develop and validate new CRISPR/Cas9-related products and solutions. The company was founded in 1999 and is based in Lyon, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "France",
        "city": "Lyon"
    },
    "KO2.F": {
        "short_name": "KORIAN S.A. INH.  EO 5",
        "long_name": "Korian",
        "summary": "Korian provides integrated health and care services for the elderly in France, Germany, Belgium, Italy, Spain, and the Netherlands. The company operates long-term care nursing homes, specialized clinics, and assisted living and shared housing facilities for seniors, as well as offers homecare and hospital-at-home services. As of June 22, 2020, it operated 893 facilities with 82,675 beds. Korian has a partnership with Aedifica to invests in new real-estate projects in the Netherlands. The company was formerly known as Korian-Medica S.A. and changed its name to Korian in July 2015. Korian was founded in 2001 and is headquartered in Paris, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "France",
        "city": "Paris"
    },
    "KORI.PA": {
        "short_name": "KORIAN",
        "long_name": "Korian",
        "summary": "Korian provides integrated health and care services for the elderly in France, Germany, Belgium, Italy, Spain, and the Netherlands. The company operates long-term care nursing homes, specialized clinics, and assisted living and shared housing facilities for seniors, as well as offers homecare and hospital-at-home services. As of June 22, 2020, it operated 893 facilities with 82,675 beds. Korian has a partnership with Aedifica to invests in new real-estate projects in the Netherlands. The company was formerly known as Korian-Medica S.A. and changed its name to Korian in July 2015. Korian was founded in 2001 and is headquartered in Paris, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Paris"
    },
    "LBIRD.PA": {
        "short_name": "LUMIBIRD",
        "long_name": "Lumibird SA",
        "summary": "Lumibird SA designs, manufactures, and markets various lasers for the scientific, industrial, and medical markets in France, Europe, the United States, and Asia. It operates in two divisions, Laser and Medical. The Laser division offers products based on fiber laser, solid-state laser, and laser diode technologies for use in industrial, defense, scientific, and medical applications. Its products primarily include solid-state lasers and pulsed laser diodes, fiber lasers and amplifiers, and laser-based electro-optical systems. The Medical division provides diagnostic and treatment equipment for ophthalmology based on lasers and ultrasonic sensors, such as lasers and echographs. The company was founded in 1970 and is based in Lannion, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Lannion"
    },
    "LNA.PA": {
        "short_name": "LNA SANTE",
        "long_name": "LNA Sant\u00e9 SA",
        "summary": "LNA Sant\u00c3\u00a9 SA operates and manages full-care facilities for the dependent elderly persons under the LNA Sant\u00c3\u00a9 brand in France and Belgium. The company operates nursing homes, follow-up care and rehabilitation facilities, home hospitalization structures, health centers, and psychiatric clinics. It serves patients with complex, acute, or chronic pathologies comprising neurological, respiratory, cardiovascular, psychiatric, etc. The company operates 11 clinics; 1 psychiatric clinic; and 7 home care facilities. LNA Sant\u00c3\u00a9 SA was founded in 1990 and is based in Vertou, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Vertou"
    },
    "LYS.PA": {
        "short_name": "LYSOGENE",
        "long_name": "Lysogene S.A.",
        "summary": "Lysogene S.A. engages in the research and clinical development of gene therapy for neurodegenerative disorders. Its clinical programs include LYS-SAF302, which is in Phase II/III clinical trial for the treatment of mucopolysaccharidosis type IIIA; and LYS-GM101 that is in Phase I/II trial for the treatment of GM1 gangliosidosis. The company has a collaborative research collaboration with the Weizmann Institute of Science for developing a novel AAV gene therapy approach for neuronopathic gaucher disease, parkinson disease, and other diseases. Lysogene S.A. was founded in 2009 and is based in Neuilly-sur-Seine, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Neuilly-sur-Seine"
    },
    "MDCLF": {
        "short_name": "MEDINCELL SA",
        "long_name": "MedinCell S.A.",
        "summary": "MedinCell S.A. develops various therapeutic solutions. It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends the active pharmaceutical ingredients. The company's products in development include mdc-IRM, a subcutaneous injection in Phase III trials for use in the treatment of schizophrenia; mdc-CWM, an intra-articular injection to treat pain and inflammation; and mdc-TJK, a subcutaneous injection in preclinical trials for use in the treatment of schizophrenia. Its product candidates in formulation research comprise subcutaneous injections, such as mdc-WWM for contraception; mdc-ANG for CNS related treatments; mdc-ELK for depression; and mdc-GRT for use in organ transplant, as well as perineural injections, including mdc-CMV for anesthesia and pain, and mdc-NVA for pain. The company is based in Jacou, France.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "France",
        "city": "Jacou"
    },
    "MEB.F": {
        "short_name": "MEDINCELL S.A.  EO-,01",
        "long_name": "MedinCell S.A.",
        "summary": "MedinCell S.A. develops various therapeutic solutions. It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends the active pharmaceutical ingredients. The company's products in development include mdc-IRM, a subcutaneous injection in Phase III trials for use in the treatment of schizophrenia; mdc-CWM, an intra-articular injection to treat pain and inflammation; and mdc-TJK, a subcutaneous injection in preclinical trials for use in the treatment of schizophrenia. Its product candidates in formulation research comprise subcutaneous injections, such as mdc-WWM for contraception; mdc-ANG for CNS related treatments; mdc-ELK for depression; and mdc-GRT for use in organ transplant, as well as perineural injections, including mdc-CMV for anesthesia and pain, and mdc-NVA for pain. The company is based in Jacou, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "France",
        "city": "Jacou"
    },
    "MEDCL.PA": {
        "short_name": "MEDINCELL",
        "long_name": "MedinCell S.A.",
        "summary": "MedinCell S.A. develops various therapeutic solutions. It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends the active pharmaceutical ingredients. The company's products in development include mdc-IRM, a subcutaneous injection in Phase III trials for use in the treatment of schizophrenia; mdc-CWM, an intra-articular injection to treat pain and inflammation; and mdc-TJK, a subcutaneous injection in preclinical trials for use in the treatment of schizophrenia. Its product candidates in formulation research comprise subcutaneous injections, such as mdc-WWM for contraception; mdc-ANG for CNS related treatments; mdc-ELK for depression; and mdc-GRT for use in organ transplant, as well as perineural injections, including mdc-CMV for anesthesia and pain, and mdc-NVA for pain. The company is based in Jacou, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Jacou"
    },
    "MKEA.PA": {
        "short_name": "MAUNA KEA TECH",
        "long_name": "Mauna Kea Technologies SA",
        "summary": "Mauna Kea Technologies SA develops and markets medical devices for the diagnosis and treatment of cancers and other diseases in Europe, the Middle East, Africa, the United States, Latin America, China, and Japan. Its flagship product is Cellvizio, a multidisciplinary probe and needle-based confocal laser endomicroscopy platform, which provides physicians and researchers with images of tissues at the cellular level. The company was founded in 2000 and is headquartered in Paris, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Paris"
    },
    "MKEAF": {
        "short_name": "MAUNA KEA TECHNOLOGIES",
        "long_name": "Mauna Kea Technologies SA",
        "summary": "Mauna Kea Technologies SA develops and markets medical devices for the diagnosis and treatment of cancers and other diseases in Europe, the Middle East, Africa, the United States, Latin America, China, and Japan. Its flagship product is Cellvizio, a multidisciplinary probe and needle-based confocal laser endomicroscopy platform, which provides physicians and researchers with images of tissues at the cellular level. The company was founded in 2000 and is headquartered in Paris, France.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "France",
        "city": "Paris"
    },
    "MLAHC.PA": {
        "short_name": "HEALTH",
        "long_name": "@Health SA",
        "summary": "@Health SA, an e-cardiology company, develops medical devices worldwide. It offers CardioNexion, a medical device for the ultra-early detection and analysis of all cardiovascular pathologies. The company is based in Aix-en-Provence, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Diagnostics & Research",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Aix-en-Provence"
    },
    "MLGML.PA": {
        "short_name": "GOUR MEDICAL",
        "long_name": "Gour Medical SA",
        "summary": "Gour Medical SA engages in the development and commercialization of veterinary drugs. The company develops various medicines and food supplements to enhance the health of mature pets. Its product portfolio includes Gour-153, a pain product; and Gour-419, an atopic dermatitis product. Gour Medical SA was founded in 2014 and is based in Paris, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers\u2014Specialty & Generic",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Paris"
    },
    "MLSBT.PA": {
        "short_name": "SBT",
        "long_name": "Scientific Brain Training SA",
        "summary": "Scientific Brain Training SA provides consultancy and human resources, and smart health services for individuals and the healthcare sector. The company provides services for the selection level of behavioral competencies, such as managerial, commercial, and operational; and advice and support training services. It also offers software solutions for healthcare professions to treat and prevent cognitive and learning disorders; and cognition and neurotraumatic, neurodegenerative, and neuropsychiatric disorders solutions for children, teenagers, adults, and seniors. Scientific Brain Training SA was founded in 2000 and is based in Lyon, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Lyon"
    },
    "NANO.PA": {
        "short_name": "NANOBIOTIX",
        "long_name": "Nanobiotix S.A.",
        "summary": "Nanobiotix SA operates as a clinical-stage nanomedicine company for the treatment of cancer worldwide. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. It offers NBTXR3, a radio-enhancer hafnium oxide for the treatment of solid tumors, including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, glioblastoma, and other cancers. Nanobiotix SA was incorporated in 2003 and is headquartered in Paris, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Paris"
    },
    "NBTX": {
        "short_name": "Nanobiotix S.A.",
        "long_name": "Nanobiotix S.A.",
        "summary": "Nanobiotix SA operates as a clinical-stage nanomedicine company for the treatment of cancer worldwide. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. It offers NBTXR3, a radio-enhancer hafnium oxide for the treatment of solid tumors, including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, glioblastoma, and other cancers. Nanobiotix SA was incorporated in 2003 and is headquartered in Paris, France.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "NMS",
        "market": "us_market",
        "country": "France",
        "city": "Paris"
    },
    "NICXF": {
        "short_name": "NICOX SA",
        "long_name": "Nicox S.A.",
        "summary": "Nicox S.A., an ophthalmology company, develops solutions to maintain ocular health in France and internationally. It offers VYZULTA, a latanoprostene bunod ophthalmic solution for open angle glaucoma or ocular hypertension; ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis; and NCX 4280, an ophthalmic solution that targets morning eye congestion. The company also develops NCX 470, a nitric oxide (NO)-donating candidate that is in Phase II clinical trial for the lowering of intraocular pressure in patients with open angle glaucoma or ocular hypertension; and NCX 4251, a patented formulation of fluticasone propionate, which is in Phase II clinical trial for patients with acute exacerbations of blepharitis. Its research product pipeline includes NO-donating phosphodiesterase-5 inhibitors. The company has collaborations with Bausch + Lomb and Ironwood Pharmaceuticals, Inc. Nicox S.A. was founded in 1996 and is headquartered in Valbonne, France.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "France",
        "city": "Valbonne"
    },
    "NXOA.F": {
        "short_name": "NICOX SA INH.  EO 1",
        "long_name": "Nicox S.A.",
        "summary": "Nicox S.A., an ophthalmology company, develops solutions to maintain ocular health in France and internationally. It offers VYZULTA, a latanoprostene bunod ophthalmic solution for open angle glaucoma or ocular hypertension; ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis; and NCX 4280, an ophthalmic solution that targets morning eye congestion. The company also develops NCX 470, a nitric oxide (NO)-donating candidate that is in Phase II clinical trial for the lowering of intraocular pressure in patients with open angle glaucoma or ocular hypertension; and NCX 4251, a patented formulation of fluticasone propionate, which is in Phase II clinical trial for patients with acute exacerbations of blepharitis. Its research product pipeline includes NO-donating phosphodiesterase-5 inhibitors. The company has collaborations with Bausch + Lomb and Ironwood Pharmaceuticals, Inc. Nicox S.A. was founded in 1996 and is headquartered in Valbonne, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "France",
        "city": "Valbonne"
    },
    "ONXEO.CO": {
        "short_name": "Onxeo SA",
        "long_name": "Onxeo SA",
        "summary": "Onxeo SA, a clinical-stage biotechnology company, designs and develops oncology drugs for tumor DNA repair functions worldwide. The company offers Beleodaq for the treatment of relapsed or refractory peripheral T-cell lymphoma. It also develops AsiDNA, which is in Phase 1 clinical trial for the treatment of metastatic melanoma; OX401, which is in preclinical stage for treating DNA damage response and immuno-oncology; and Validive, which completed Phase II clinical trial for the treatment of oral mucositis in patients treated for a head and neck cancer. Onxeo SA has a collaboration and licensing agreement with Spectrum Pharmaceuticals for the development of Beleodaq; a license agreement with Monopar Therapeutics Inc. to develop Validive; and clinical research agreement with Gustave Roussy to conduct clinical trial of AsiDNA for the treatment of relapsed ovarian cancer. The company was formerly known as BioAlliance Pharma SA and changed its name to Onxeo SA in July 2014. Onxeo SA was founded in 1997 and is headquartered in Paris, France.",
        "currency": "DKK",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "CPH",
        "market": "dk_market",
        "country": "France",
        "city": "Paris"
    },
    "OPA.F": {
        "short_name": "ORPEA  ACT.NOM. EO 1,25",
        "long_name": "Orpea SA",
        "summary": "ORPEA SA operates nursing homes, assisted-living facilities, post-acute and rehabilitation hospitals, and psychiatric hospitals. Its nursing home facilities provide personalized support services; and logistical and residential services, including accommodation, meals, laundry and room cleaning, and various daily entertainment and therapeutic workshop services. The company's post-acute and rehabilitation hospitals offer services for geriatrics, musculoskeletal, nervous system, cardiovascular, hematology, and oncology conditions, as well as patients in a persistent vegetative state or in a minimally conscious state. Its psychiatric hospitals provide services for the patients with mood disorders, anxiety disorders, obsessive-compulsive disorders, addictions, eating disorders, sleep disorders, personality disorders, ageing-related psychiatric disorders, psychosis, over exhaustion or burn-out, chronic fatigue syndrome, fibromyalgia, and psychosomatic conditions, as well as geriatric, child, young, parent-child, and public/private patients psychiatry services. In addition, the company offers home care services, including housekeeping services, such as cleaning, meals, ironing, gardening, and household errands; daily life assistance services comprising day or night supervision, assistance with hygiene tasks, and meal-time assistance; and movement assistance services. As of May 5, 2020, it operated 1,014 facilities with 104,234 beds. The company operates in France, Belgium, Spain, Italy, Switzerland, Austria, Germany, the Czech Republic, Poland, the Netherlands, Luxembourg, Austria, Portugal, Brazil, Russia, Slovenia, Uruguay, Colombia, Mexico, and China. ORPEA SA was founded in 1989 and is headquartered in Puteaux, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "France",
        "city": "Puteaux"
    },
    "OR9A.F": {
        "short_name": "SAFE ORTHOPAEDICS EO 0,10",
        "long_name": "Safe Orthopaedics SA",
        "summary": "Safe Orthopaedics SA, a medical technology company, develops and markets sterile implants and single-use instruments for the treatment of spinal fracture pathologies in France and internationally. The company offers SteriSpine PS, an all-round kit for the treatment of spinal fractures and degenerative pathologies; and SteriSpine VA, a product platform for ready to use Kyphoplasty and Cement systems. It also provides SteriSpine LC, a ready to use instrumentation for lumbar cage portfolio, including Cedar and Elm; and SteriSpine CC, a ready to use instrumentation for cervical cage, such as Walnut. The company was founded in 2010 and is headquartered in \u00c3\u0089ragny-sur-Oise, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "France",
        "city": "Eragny-sur-Oise"
    },
    "ORP.PA": {
        "short_name": "ORPEA",
        "long_name": "Orpea SA",
        "summary": "ORPEA SA operates nursing homes, assisted-living facilities, post-acute and rehabilitation hospitals, and psychiatric hospitals. Its nursing home facilities provide personalized support services; and logistical and residential services, including accommodation, meals, laundry and room cleaning, and various daily entertainment and therapeutic workshop services. The company's post-acute and rehabilitation hospitals offer services for geriatrics, musculoskeletal, nervous system, cardiovascular, hematology, and oncology conditions, as well as patients in a persistent vegetative state or in a minimally conscious state. Its psychiatric hospitals provide services for the patients with mood disorders, anxiety disorders, obsessive-compulsive disorders, addictions, eating disorders, sleep disorders, personality disorders, ageing-related psychiatric disorders, psychosis, over exhaustion or burn-out, chronic fatigue syndrome, fibromyalgia, and psychosomatic conditions, as well as geriatric, child, young, parent-child, and public/private patients psychiatry services. In addition, the company offers home care services, including housekeeping services, such as cleaning, meals, ironing, gardening, and household errands; daily life assistance services comprising day or night supervision, assistance with hygiene tasks, and meal-time assistance; and movement assistance services. As of May 5, 2020, it operated 1,014 facilities with 104,234 beds. The company operates in France, Belgium, Spain, Italy, Switzerland, Austria, Germany, the Czech Republic, Poland, the Netherlands, Luxembourg, Austria, Portugal, Brazil, Russia, Slovenia, Uruguay, Colombia, Mexico, and China. ORPEA SA was founded in 1989 and is headquartered in Puteaux, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Puteaux"
    },
    "ORP.VI": {
        "short_name": "ORPEA",
        "long_name": "Orpea SA",
        "summary": "ORPEA SA operates nursing homes, assisted-living facilities, post-acute and rehabilitation hospitals, and psychiatric hospitals. Its nursing home facilities provide personalized support services; and logistical and residential services, including accommodation, meals, laundry and room cleaning, and various daily entertainment and therapeutic workshop services. The company's post-acute and rehabilitation hospitals offer services for geriatrics, musculoskeletal, nervous system, cardiovascular, hematology, and oncology conditions, as well as patients in a persistent vegetative state or in a minimally conscious state. Its psychiatric hospitals provide services for the patients with mood disorders, anxiety disorders, obsessive-compulsive disorders, addictions, eating disorders, sleep disorders, personality disorders, ageing-related psychiatric disorders, psychosis, over exhaustion or burn-out, chronic fatigue syndrome, fibromyalgia, and psychosomatic conditions, as well as geriatric, child, young, parent-child, and public/private patients psychiatry services. In addition, the company offers home care services, including housekeeping services, such as cleaning, meals, ironing, gardening, and household errands; daily life assistance services comprising day or night supervision, assistance with hygiene tasks, and meal-time assistance; and movement assistance services. As of May 5, 2020, it operated 1,014 facilities with 104,234 beds. The company operates in France, Belgium, Spain, Italy, Switzerland, Austria, Germany, the Czech Republic, Poland, the Netherlands, Luxembourg, Austria, Portugal, Brazil, Russia, Slovenia, Uruguay, Colombia, Mexico, and China. ORPEA SA was founded in 1989 and is headquartered in Puteaux, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "VIE",
        "market": "at_market",
        "country": "France",
        "city": "Puteaux"
    },
    "ORPEF": {
        "short_name": "ORPEA",
        "long_name": "Orpea SA",
        "summary": "ORPEA SA operates nursing homes, assisted-living facilities, post-acute and rehabilitation hospitals, and psychiatric hospitals. Its nursing home facilities provide personalized support services; and logistical and residential services, including accommodation, meals, laundry and room cleaning, and various daily entertainment and therapeutic workshop services. The company's post-acute and rehabilitation hospitals offer services for geriatrics, musculoskeletal, nervous system, cardiovascular, hematology, and oncology conditions, as well as patients in a persistent vegetative state or in a minimally conscious state. Its psychiatric hospitals provide services for the patients with mood disorders, anxiety disorders, obsessive-compulsive disorders, addictions, eating disorders, sleep disorders, personality disorders, ageing-related psychiatric disorders, psychosis, over exhaustion or burn-out, chronic fatigue syndrome, fibromyalgia, and psychosomatic conditions, as well as geriatric, child, young, parent-child, and public/private patients psychiatry services. In addition, the company offers home care services, including housekeeping services, such as cleaning, meals, ironing, gardening, and household errands; daily life assistance services comprising day or night supervision, assistance with hygiene tasks, and meal-time assistance; and movement assistance services. As of May 5, 2020, it operated 1,014 facilities with 104,234 beds. The company operates in France, Belgium, Spain, Italy, Switzerland, Austria, Germany, the Czech Republic, Poland, the Netherlands, Luxembourg, Austria, Portugal, Brazil, Russia, Slovenia, Uruguay, Colombia, Mexico, and China. ORPEA SA was founded in 1989 and is headquartered in Puteaux, France.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Care Facilities",
        "exchange": "PNK",
        "market": "us_market",
        "country": "France",
        "city": "Puteaux"
    },
    "P0X.SG": {
        "short_name": "Pharnext Actions Nom. EO-,01",
        "long_name": "Pharnext SA",
        "summary": "Pharnext SA, a clinical-stage biopharmaceutical company, develops therapies for orphan and common neurodegenerative diseases in France. The company's products include SYNGILITY that has completed Phase III trial for the treatment of Charcot-Marie-Tooth disease type 1A; and PXT864, which has completed Phase II clinical trial to treat Alzheimer's disease, as well as Parkinson's disease and amyotrophic lateral sclerosis. It also develops PLEOTHERAPY, a big genetic data and artificial intelligence platform. Pharnext SA has an agreement with the University Hospital Institute Mediterranee Infection to evaluate repurposed drugs for potential use against the COVID-19 virus. The company was founded in 2007 and is headquartered in Issy-Les-Moulineaux, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STU",
        "market": "dr_market",
        "country": "France",
        "city": "Issy-les-Moulineaux"
    },
    "PHF.F": {
        "short_name": "PHARMAGEST INT.INH.EO 0,2",
        "long_name": "Pharmagest Interactive SA",
        "summary": "Pharmagest Interactive SA engages in the development and commercialization of IT solutions for pharmacies and the pharmaceutical industry in Europe. It offers solution for managing pharmacies and their networks, such as LGPI global services and OffCentral; security solutions for pharmacists' business processes, such as OffMSS, OffSecure, DomiSecure, OffProtect, OffPass, OffSeen, OffCash, and Offzzy; solutions for energising the customer relationship with pharmacists, including OffTag, OffTouch, OffM\u00c3\u00a9dia, and OffConnect, as well as automation systems, such as SELLEN, SELLEN TWIST, and SINTESI robots that optimize the available space and free up the pharmacies team to advise customers; and customer loyalty programmes. The company also provides My Pilot, an analytics and management tool equipped with dashboards; OffLearning, e-learning tool; solutions for patient support and advice, such as the compliance monitoring software, Ma Pharmacie Mobile, Multimeds, Automeds, OffT\u00c3\u00a9l\u00c3\u00a9consult, as well as provides pharmaceutical record and shared medical record. In addition, it offers a range of PHARMAGEST BELGIUM software for the pharmacies in Belgium; OFFICINE 2016 pharmacy software management suite for Luxembourg; TITAN, an integrated and modular software suite for elderly residential care homes, day care and sheltered housing facilities for persons with disabilities. Further, the company provides hospital-at-home solutions, such as ANTHADINE and MOBISOINS; MICROSOINS, an in-home nursing care solution; and LOGICLIC that provides services for local information and coordination centres. Additionally, it offers equipment lease financing solutions; and IT equipment and services to wholesale distributors, such as DIFARM, FARMACLICK, PHARE, and SOPHIA. The company was founded in 1996 and is based in Villers-les-Nancy, France. Pharmagest Interactive SA is a subsidiary of Marque Verte Sante.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "France",
        "city": "Villers-l\u00c3\u00a8s-Nancy"
    },
    "PNEXF": {
        "short_name": "PHARNEXT",
        "long_name": "Pharnext SA",
        "summary": "Pharnext SA, a clinical-stage biopharmaceutical company, develops therapies for orphan and common neurodegenerative diseases in France. The company's products include SYNGILITY that has completed Phase III trial for the treatment of Charcot-Marie-Tooth disease type 1A; and PXT864, which has completed Phase II clinical trial to treat Alzheimer's disease, as well as Parkinson's disease and amyotrophic lateral sclerosis. It also develops PLEOTHERAPY, a big genetic data and artificial intelligence platform. Pharnext SA has an agreement with the University Hospital Institute Mediterranee Infection to evaluate repurposed drugs for potential use against the COVID-19 virus. The company was founded in 2007 and is headquartered in Issy-Les-Moulineaux, France.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "France",
        "city": "Issy-les-Moulineaux"
    },
    "POXEL.PA": {
        "short_name": "POXEL",
        "long_name": "Poxel S.A.",
        "summary": "Poxel S.A., a biopharmaceutical company, develops drugs for metabolic diseases with primary focus on type II diabetes. Its lead product is Imeglimin, an oral anti-diabetic candidate, which is in Phase III clinical development stage that targets the organs of diabetes, such as pancreas, liver, and muscles. The company is also developing PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in Phase IIa clinical trial that controls body energy metabolism and treats chronic metabolic diseases, such as non-alcoholic steatohepatitis (NASH). It has a licensing agreement with Enyo Pharma for the development of PXL007 (EYP001), an FXR agonist that is in Phase I study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial pyruvate carrier inhibitor, which is in phase I clinical trials for the treatment of NASH. The company was founded in 2009 and is headquartered in Lyon, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Lyon"
    },
    "PXH.F": {
        "short_name": "PIXIUM VISION SA  EO -,06",
        "long_name": "Pixium Vision SA",
        "summary": "Pixium Vision SA, a bioelectronics and brain machine interface technology company, specialized in neuromodulation application. It develops PRIMA System, a bionic vision system to treat blindness caused by degeneration of photoreceptor cells in the retina. The company has collaboration agreements with Stanford University in California, Institut de la Vision, Moorfields Eye Hospital, Institute of Ocular Microsurgery, University Hospital, and UPMC. Pixium Vision SA was founded in 2011 and is based in Paris, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "France",
        "city": "Paris"
    },
    "RFM.SG": {
        "short_name": "Sensorion S.A. Actions au Porte",
        "long_name": "Sensorion SA",
        "summary": "Sensorion SA, a biopharmaceutical company, develops therapies for the treatment of inner ear disorders. The company develops SENS-111, which is in phase II clinical trials to treat acute unilateral vestibulopathy; and SENS-401 that is in phase I clinical trials to treat sudden sensorineural hearing loss. It also develops SENS-300, which is under the pre-clinical stage for use in inner ear toxicity treatment. The company has a strategic collaboration with Cochlear Limited to study combination therapies for cochlear implant patients. Sensorion SA was founded in 2009 and is headquartered in Montpellier, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STU",
        "market": "dr_market",
        "country": "France",
        "city": "Montpellier"
    },
    "SAN.PA": {
        "short_name": "SANOFI",
        "long_name": "Sanofi",
        "summary": "Sanofi provides therapeutic solutions worldwide. It offers Cerezyme and Cerdelga for Gaucher, Myozyme and Lumizyme for Pompe, Fabrazyme for Fabry, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio and Lemtrada for multiple sclerosis. It also provides Dupixent for atopic dermatitis; Kevzara for rheumatoid arthritis; Eloctate and Alprolix to treat hemophilia; and Cablivi to treat acquired thrombotic thrombocytopenic purpura. In addition, it offers Libtayo for metastatic cutaneous squamous cell carcinoma; Jevtana and Taxotere taxane for cancers; Eloxatin for colon cancer; Thymoglobulin, an immunosuppressive and immunomodulating agent; Mozobil for hematologic malignancies; and Zaltrap for metastatic colorectal cancer. Further, it provides Lantus, Toujeo, Apidra, and Insuman insulins; Amaryl sulfonylurea; Adlyxin/Lyxumia, a GLP-1 receptor agonist; Soliqua 100/33/Suliqua, an insulin glargine and lixisenatide combination to treat diabetes; Admelog/Insulin lispro insulin; Praluent, a cholesterol-lowering drug; and Multaq, an anti-arrhythmic drug. Additionally, it offers Plavix for atherothrombotic conditions; Lovenox for the prophylaxis, venous thromboembolism, and acute coronary syndrome; Aprovel and CoAprovel anti-hypertensives; Renagel and Renvela for patients undergoing dialysis; Synvisc and Synvisc-One viscosupplements for osteoarthritis; Stilnox for insomnia; Allegra for seasonal allergic rhinitis and uncomplicated hives; and Depakine for epilepsy. It also provides generic products; and products for allergy, cough, cold, pain, nutrition, digestion, pediatrics, influenza, meningitis, travel, and endemic vaccines; and adult and adolescent boosters. Sanofi has collaborations with Verily Life Sciences LLC; Happify Health; GlaxoSmithKline Plc; Kymera Therapeutics; Parkinson's Foundation, Inc.; and Nurix Therapeutics, Inc. The company was formerly known as Sanofi-Aventis. Sanofi was incorporated in 1994 and is headquartered in Paris, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers\u2014General",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Paris"
    },
    "SANF.MI": {
        "short_name": "SANOFI",
        "long_name": "Sanofi",
        "summary": "Sanofi provides therapeutic solutions worldwide. It offers Cerezyme and Cerdelga for Gaucher, Myozyme and Lumizyme for Pompe, Fabrazyme for Fabry, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio and Lemtrada for multiple sclerosis. It also provides Dupixent for atopic dermatitis; Kevzara for rheumatoid arthritis; Eloctate and Alprolix to treat hemophilia; and Cablivi to treat acquired thrombotic thrombocytopenic purpura. In addition, it offers Libtayo for metastatic cutaneous squamous cell carcinoma; Jevtana and Taxotere taxane for cancers; Eloxatin for colon cancer; Thymoglobulin, an immunosuppressive and immunomodulating agent; Mozobil for hematologic malignancies; and Zaltrap for metastatic colorectal cancer. Further, it provides Lantus, Toujeo, Apidra, and Insuman insulins; Amaryl sulfonylurea; Adlyxin/Lyxumia, a GLP-1 receptor agonist; Soliqua 100/33/Suliqua, an insulin glargine and lixisenatide combination to treat diabetes; Admelog/Insulin lispro insulin; Praluent, a cholesterol-lowering drug; and Multaq, an anti-arrhythmic drug. Additionally, it offers Plavix for atherothrombotic conditions; Lovenox for the prophylaxis, venous thromboembolism, and acute coronary syndrome; Aprovel and CoAprovel anti-hypertensives; Renagel and Renvela for patients undergoing dialysis; Synvisc and Synvisc-One viscosupplements for osteoarthritis; Stilnox for insomnia; Allegra for seasonal allergic rhinitis and uncomplicated hives; and Depakine for epilepsy. It also provides generic products; and products for allergy, cough, cold, pain, nutrition, digestion, pediatrics, influenza, meningitis, travel, and endemic vaccines; and adult and adolescent boosters. Sanofi has collaborations with Verily Life Sciences LLC; Happify Health; GlaxoSmithKline Plc; Kymera Therapeutics; Parkinson's Foundation, Inc.; and Nurix Therapeutics, Inc. The company was formerly known as Sanofi-Aventis. Sanofi was incorporated in 1994 and is headquartered in Paris, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers\u2014General",
        "exchange": "MIL",
        "market": "it_market",
        "country": "France",
        "city": "Paris"
    },
    "SANO.VI": {
        "short_name": "SANOFI SA",
        "long_name": "Sanofi",
        "summary": "Sanofi provides therapeutic solutions worldwide. It offers Cerezyme and Cerdelga for Gaucher, Myozyme and Lumizyme for Pompe, Fabrazyme for Fabry, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio and Lemtrada for multiple sclerosis. It also provides Dupixent for atopic dermatitis; Kevzara for rheumatoid arthritis; Eloctate and Alprolix to treat hemophilia; and Cablivi to treat acquired thrombotic thrombocytopenic purpura. In addition, it offers Libtayo for metastatic cutaneous squamous cell carcinoma; Jevtana and Taxotere taxane for cancers; Eloxatin for colon cancer; Thymoglobulin, an immunosuppressive and immunomodulating agent; Mozobil for hematologic malignancies; and Zaltrap for metastatic colorectal cancer. Further, it provides Lantus, Toujeo, Apidra, and Insuman insulins; Amaryl sulfonylurea; Adlyxin/Lyxumia, a GLP-1 receptor agonist; Soliqua 100/33/Suliqua, an insulin glargine and lixisenatide combination to treat diabetes; Admelog/Insulin lispro insulin; Praluent, a cholesterol-lowering drug; and Multaq, an anti-arrhythmic drug. Additionally, it offers Plavix for atherothrombotic conditions; Lovenox for the prophylaxis, venous thromboembolism, and acute coronary syndrome; Aprovel and CoAprovel anti-hypertensives; Renagel and Renvela for patients undergoing dialysis; Synvisc and Synvisc-One viscosupplements for osteoarthritis; Stilnox for insomnia; Allegra for seasonal allergic rhinitis and uncomplicated hives; and Depakine for epilepsy. It also provides generic products; and products for allergy, cough, cold, pain, nutrition, digestion, pediatrics, influenza, meningitis, travel, and endemic vaccines; and adult and adolescent boosters. Sanofi has collaborations with Verily Life Sciences LLC; Happify Health; GlaxoSmithKline Plc; Kymera Therapeutics; Parkinson's Foundation, Inc.; and Nurix Therapeutics, Inc. The company was formerly known as Sanofi-Aventis. Sanofi was incorporated in 1994 and is headquartered in Paris, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers\u2014General",
        "exchange": "VIE",
        "market": "at_market",
        "country": "France",
        "city": "Paris"
    },
    "SDMHF": {
        "short_name": "SARTORIUS STEDIM BIOTECH",
        "long_name": "Sartorius Stedim Biotech S.A.",
        "summary": "Sartorius Stedim Biotech S.A. produces and sells instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; and a range of products for separation, purification, and concentration processes, as well as systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, filtration, purification, fluid management services, and membrane chromatography services. In addition, the company offers data analytics software for modeling and optimizing processed of biopharmaceutical development and production. It serves manufacturers of pharmaceuticals, foods, and chemicals, as well as research and development laboratories. The company was founded in 1870 and is headquartered in Aubagne, France. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Instruments & Supplies",
        "exchange": "PNK",
        "market": "us_market",
        "country": "France",
        "city": "Aubagne"
    },
    "SDT.PA": {
        "short_name": "VISIODENT",
        "long_name": "Visiodent S.A.",
        "summary": "Visiodent S.A. engages in the digital imaging and dental software businesses worldwide. The company offers phosphor plates scanners under the ISCAN brand name; RSV5 sensor systems; Visiocam 4 cameras; and dental imaging software under the Visiodent Imaging brand. Visiodent S.A. offers its products through distributors. The company was founded in 1982 and is based in La Plaine Saint-Denis, France. Visiodent S.A. is a subsidiary of Groupe Visiodent SAS.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "La Plaine Saint-Denis"
    },
    "SIGHT.PA": {
        "short_name": "GENSIGHT BIOLOGICS",
        "long_name": "GenSight Biologics S.A.",
        "summary": "GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery and development of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial target sequence and optogenetics technology platforms. Its lead product candidates include GS010, an AAV2 based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by mutation of the ND4 gene; and GS030 that is in Phase I/II trial for the treatment of retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. The company is also developing products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. GenSight Biologics S.A. was founded in 2012 and is headquartered in Paris, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Paris"
    },
    "SNW.DE": {
        "short_name": "SANOFI SA INHABER  EO 2",
        "long_name": "Sanofi",
        "summary": "Sanofi provides therapeutic solutions worldwide. It offers Cerezyme and Cerdelga for Gaucher, Myozyme and Lumizyme for Pompe, Fabrazyme for Fabry, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio and Lemtrada for multiple sclerosis. It also provides Dupixent for atopic dermatitis; Kevzara for rheumatoid arthritis; Eloctate and Alprolix to treat hemophilia; and Cablivi to treat acquired thrombotic thrombocytopenic purpura. In addition, it offers Libtayo for metastatic cutaneous squamous cell carcinoma; Jevtana and Taxotere taxane for cancers; Eloxatin for colon cancer; Thymoglobulin, an immunosuppressive and immunomodulating agent; Mozobil for hematologic malignancies; and Zaltrap for metastatic colorectal cancer. Further, it provides Lantus, Toujeo, Apidra, and Insuman insulins; Amaryl sulfonylurea; Adlyxin/Lyxumia, a GLP-1 receptor agonist; Soliqua 100/33/Suliqua, an insulin glargine and lixisenatide combination to treat diabetes; Admelog/Insulin lispro insulin; Praluent, a cholesterol-lowering drug; and Multaq, an anti-arrhythmic drug. Additionally, it offers Plavix for atherothrombotic conditions; Lovenox for the prophylaxis, venous thromboembolism, and acute coronary syndrome; Aprovel and CoAprovel anti-hypertensives; Renagel and Renvela for patients undergoing dialysis; Synvisc and Synvisc-One viscosupplements for osteoarthritis; Stilnox for insomnia; Allegra for seasonal allergic rhinitis and uncomplicated hives; and Depakine for epilepsy. It also provides generic products; and products for allergy, cough, cold, pain, nutrition, digestion, pediatrics, influenza, meningitis, travel, and endemic vaccines; and adult and adolescent boosters. Sanofi has collaborations with Verily Life Sciences LLC; Happify Health; GlaxoSmithKline Plc; Kymera Therapeutics; Parkinson's Foundation, Inc.; and Nurix Therapeutics, Inc. The company was formerly known as Sanofi-Aventis. Sanofi was incorporated in 1994 and is headquartered in Paris, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers\u2014General",
        "exchange": "GER",
        "market": "de_market",
        "country": "France",
        "city": "Paris"
    },
    "SNW.F": {
        "short_name": "SANOFI SA INHABER  EO 2",
        "long_name": "Sanofi",
        "summary": "Sanofi provides therapeutic solutions worldwide. It offers Cerezyme and Cerdelga for Gaucher, Myozyme and Lumizyme for Pompe, Fabrazyme for Fabry, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio and Lemtrada for multiple sclerosis. It also provides Dupixent for atopic dermatitis; Kevzara for rheumatoid arthritis; Eloctate and Alprolix to treat hemophilia; and Cablivi to treat acquired thrombotic thrombocytopenic purpura. In addition, it offers Libtayo for metastatic cutaneous squamous cell carcinoma; Jevtana and Taxotere taxane for cancers; Eloxatin for colon cancer; Thymoglobulin, an immunosuppressive and immunomodulating agent; Mozobil for hematologic malignancies; and Zaltrap for metastatic colorectal cancer. Further, it provides Lantus, Toujeo, Apidra, and Insuman insulins; Amaryl sulfonylurea; Adlyxin/Lyxumia, a GLP-1 receptor agonist; Soliqua 100/33/Suliqua, an insulin glargine and lixisenatide combination to treat diabetes; Admelog/Insulin lispro insulin; Praluent, a cholesterol-lowering drug; and Multaq, an anti-arrhythmic drug. Additionally, it offers Plavix for atherothrombotic conditions; Lovenox for the prophylaxis, venous thromboembolism, and acute coronary syndrome; Aprovel and CoAprovel anti-hypertensives; Renagel and Renvela for patients undergoing dialysis; Synvisc and Synvisc-One viscosupplements for osteoarthritis; Stilnox for insomnia; Allegra for seasonal allergic rhinitis and uncomplicated hives; and Depakine for epilepsy. It also provides generic products; and products for allergy, cough, cold, pain, nutrition, digestion, pediatrics, influenza, meningitis, travel, and endemic vaccines; and adult and adolescent boosters. Sanofi has collaborations with Verily Life Sciences LLC; Happify Health; GlaxoSmithKline Plc; Kymera Therapeutics; Parkinson's Foundation, Inc.; and Nurix Therapeutics, Inc. The company was formerly known as Sanofi-Aventis. Sanofi was incorporated in 1994 and is headquartered in Paris, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers\u2014General",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "France",
        "city": "Paris"
    },
    "SNY": {
        "short_name": "Sanofi",
        "long_name": "Sanofi",
        "summary": "Sanofi provides therapeutic solutions worldwide. It offers Cerezyme and Cerdelga for Gaucher, Myozyme and Lumizyme for Pompe, Fabrazyme for Fabry, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio and Lemtrada for multiple sclerosis. It also provides Dupixent for atopic dermatitis; Kevzara for rheumatoid arthritis; Eloctate and Alprolix to treat hemophilia; and Cablivi to treat acquired thrombotic thrombocytopenic purpura. In addition, it offers Libtayo for metastatic cutaneous squamous cell carcinoma; Jevtana and Taxotere taxane for cancers; Eloxatin for colon cancer; Thymoglobulin, an immunosuppressive and immunomodulating agent; Mozobil for hematologic malignancies; and Zaltrap for metastatic colorectal cancer. Further, it provides Lantus, Toujeo, Apidra, and Insuman insulins; Amaryl sulfonylurea; Adlyxin/Lyxumia, a GLP-1 receptor agonist; Soliqua 100/33/Suliqua, an insulin glargine and lixisenatide combination to treat diabetes; Admelog/Insulin lispro insulin; Praluent, a cholesterol-lowering drug; and Multaq, an anti-arrhythmic drug. Additionally, it offers Plavix for atherothrombotic conditions; Lovenox for the prophylaxis, venous thromboembolism, and acute coronary syndrome; Aprovel and CoAprovel anti-hypertensives; Renagel and Renvela for patients undergoing dialysis; Synvisc and Synvisc-One viscosupplements for osteoarthritis; Stilnox for insomnia; Allegra for seasonal allergic rhinitis and uncomplicated hives; and Depakine for epilepsy. It also provides generic products; and products for allergy, cough, cold, pain, nutrition, digestion, pediatrics, influenza, meningitis, travel, and endemic vaccines; and adult and adolescent boosters. Sanofi has collaborations with Verily Life Sciences LLC; Happify Health; GlaxoSmithKline Plc; Kymera Therapeutics; Parkinson's Foundation, Inc.; and Nurix Therapeutics, Inc. The company was formerly known as Sanofi-Aventis. Sanofi was incorporated in 1994 and is headquartered in Paris, France.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers\u2014General",
        "exchange": "NMS",
        "market": "us_market",
        "country": "France",
        "city": "Paris"
    },
    "SNYN.MX": {
        "short_name": "SANOFI",
        "long_name": "Sanofi",
        "summary": "Sanofi provides therapeutic solutions worldwide. It offers Cerezyme and Cerdelga for Gaucher, Myozyme and Lumizyme for Pompe, Fabrazyme for Fabry, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio and Lemtrada for multiple sclerosis. It also provides Dupixent for atopic dermatitis; Kevzara for rheumatoid arthritis; Eloctate and Alprolix to treat hemophilia; and Cablivi to treat acquired thrombotic thrombocytopenic purpura. In addition, it offers Libtayo for metastatic cutaneous squamous cell carcinoma; Jevtana and Taxotere taxane for cancers; Eloxatin for colon cancer; Thymoglobulin, an immunosuppressive and immunomodulating agent; Mozobil for hematologic malignancies; and Zaltrap for metastatic colorectal cancer. Further, it provides Lantus, Toujeo, Apidra, and Insuman insulins; Amaryl sulfonylurea; Adlyxin/Lyxumia, a GLP-1 receptor agonist; Soliqua 100/33/Suliqua, an insulin glargine and lixisenatide combination to treat diabetes; Admelog/Insulin lispro insulin; Praluent, a cholesterol-lowering drug; and Multaq, an anti-arrhythmic drug. Additionally, it offers Plavix for atherothrombotic conditions; Lovenox for the prophylaxis, venous thromboembolism, and acute coronary syndrome; Aprovel and CoAprovel anti-hypertensives; Renagel and Renvela for patients undergoing dialysis; Synvisc and Synvisc-One viscosupplements for osteoarthritis; Stilnox for insomnia; Allegra for seasonal allergic rhinitis and uncomplicated hives; and Depakine for epilepsy. It also provides generic products; and products for allergy, cough, cold, pain, nutrition, digestion, pediatrics, influenza, meningitis, travel, and endemic vaccines; and adult and adolescent boosters. Sanofi has collaborations with Verily Life Sciences LLC; Happify Health; GlaxoSmithKline Plc; Kymera Therapeutics; Parkinson's Foundation, Inc.; and Nurix Therapeutics, Inc. The company was formerly known as Sanofi-Aventis. Sanofi was incorporated in 1994 and is headquartered in Paris, France.",
        "currency": "MXN",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers - Major",
        "exchange": "MEX",
        "market": "mx_market",
        "country": "France",
        "city": "Paris"
    },
    "SNYNF": {
        "short_name": "SANOFI",
        "long_name": "Sanofi",
        "summary": "Sanofi provides therapeutic solutions worldwide. It offers Cerezyme and Cerdelga for Gaucher, Myozyme and Lumizyme for Pompe, Fabrazyme for Fabry, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio and Lemtrada for multiple sclerosis. It also provides Dupixent for atopic dermatitis; Kevzara for rheumatoid arthritis; Eloctate and Alprolix to treat hemophilia; and Cablivi to treat acquired thrombotic thrombocytopenic purpura. In addition, it offers Libtayo for metastatic cutaneous squamous cell carcinoma; Jevtana and Taxotere taxane for cancers; Eloxatin for colon cancer; Thymoglobulin, an immunosuppressive and immunomodulating agent; Mozobil for hematologic malignancies; and Zaltrap for metastatic colorectal cancer. Further, it provides Lantus, Toujeo, Apidra, and Insuman insulins; Amaryl sulfonylurea; Adlyxin/Lyxumia, a GLP-1 receptor agonist; Soliqua 100/33/Suliqua, an insulin glargine and lixisenatide combination to treat diabetes; Admelog/Insulin lispro insulin; Praluent, a cholesterol-lowering drug; and Multaq, an anti-arrhythmic drug. Additionally, it offers Plavix for atherothrombotic conditions; Lovenox for the prophylaxis, venous thromboembolism, and acute coronary syndrome; Aprovel and CoAprovel anti-hypertensives; Renagel and Renvela for patients undergoing dialysis; Synvisc and Synvisc-One viscosupplements for osteoarthritis; Stilnox for insomnia; Allegra for seasonal allergic rhinitis and uncomplicated hives; and Depakine for epilepsy. It also provides generic products; and products for allergy, cough, cold, pain, nutrition, digestion, pediatrics, influenza, meningitis, travel, and endemic vaccines; and adult and adolescent boosters. Sanofi has collaborations with Verily Life Sciences LLC; Happify Health; GlaxoSmithKline Plc; Kymera Therapeutics; Parkinson's Foundation, Inc.; and Nurix Therapeutics, Inc. The company was formerly known as Sanofi-Aventis. Sanofi was incorporated in 1994 and is headquartered in Paris, France.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers\u2014General",
        "exchange": "PNK",
        "market": "us_market",
        "country": "France",
        "city": "Paris"
    },
    "TCLIF": {
        "short_name": "THERACLION",
        "long_name": "Theraclion Soci\u00e9t\u00e9 anonyme",
        "summary": "Theraclion Soci\u00c3\u00a9t\u00c3\u00a9 anonyme develops, manufactures, and markets therapeutic ultrasound equipment. It offers an echotherapy solution that combines high-intensity focused ultrasound therapy with ultrasound as a system for locating target areas for the non-invasive treatment of benign tumours. The company also offers Echopulse for the non-invasive and ambulatory treatment of breast fibroadenomas and benign thyroid nodules to practitioners; and SONOVEIN, an echotherapy solution using therapeutic ultrasound for the treatment of varicose veins. It operates in approximately 20 countries worldwide. The company was founded in 2004 and is based in Malakoff, France.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Medical Devices",
        "exchange": "PNK",
        "market": "us_market",
        "country": "France",
        "city": "Malakoff"
    },
    "TGNA.F": {
        "short_name": "TRANSGENE SA  EO 0,50",
        "long_name": "Transgene SA",
        "summary": "Transgene SA, a biotechnology company, designs, develops, and produces therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. The company's lead clinical-stage programs include TG4010, a therapeutic vaccine for the treatment of non-small cell lung cancer; Pexa-Vec, an oncolytic virus for the treatment of liver cancer; and TG4001, a therapeutic vaccine for cancers caused by the human papilloma virus. Its products in the clinical development stage also comprise TG1050, a therapeutic vaccine for the treatment of chronic hepatitis B; and TG6002, an oncolytic virus for the treatment of various solid tumors, such as glioblastoma, as well as for the cancers of the stomach, colon, pancreas, and bladder. Transgene SA has collaboration agreements with Bristol-Myers Squibb, Merck KGaA, Pfizer, and University of California Davis; licensing agreements with SillaJen, Inc. and Ascend BioPharmaceutical; agreements with Sanofi, BioInvent, Randox, and Emergent BioSolutions Inc.; collaboration and licensing agreement with Valneva; a strategic collaboration with NEC Corporation; and a collaboration with BioInvent International AB (publ) to co-develop multi-functional oncolytic viruses encoding for undisclosed antibodies sequences for treating a range of solid tumors. It also has a collaborative research and license agreement with AstraZeneca to co-develop five armed oncolytic vaccinia virus candidates. The company was founded in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "France",
        "city": "Illkirch-Graffenstaden"
    },
    "TNG.PA": {
        "short_name": "TRANSGENE",
        "long_name": "Transgene SA",
        "summary": "Transgene SA, a biotechnology company, designs, develops, and produces therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. The company's lead clinical-stage programs include TG4010, a therapeutic vaccine for the treatment of non-small cell lung cancer; Pexa-Vec, an oncolytic virus for the treatment of liver cancer; and TG4001, a therapeutic vaccine for cancers caused by the human papilloma virus. Its products in the clinical development stage also comprise TG1050, a therapeutic vaccine for the treatment of chronic hepatitis B; and TG6002, an oncolytic virus for the treatment of various solid tumors, such as glioblastoma, as well as for the cancers of the stomach, colon, pancreas, and bladder. Transgene SA has collaboration agreements with Bristol-Myers Squibb, Merck KGaA, Pfizer, and University of California Davis; licensing agreements with SillaJen, Inc. and Ascend BioPharmaceutical; agreements with Sanofi, BioInvent, Randox, and Emergent BioSolutions Inc.; collaboration and licensing agreement with Valneva; a strategic collaboration with NEC Corporation; and a collaboration with BioInvent International AB (publ) to co-develop multi-functional oncolytic viruses encoding for undisclosed antibodies sequences for treating a range of solid tumors. It also has a collaborative research and license agreement with AstraZeneca to co-develop five armed oncolytic vaccinia virus candidates. The company was founded in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Illkirch-Graffenstaden"
    },
    "TRGNF": {
        "short_name": "TRANSGENE",
        "long_name": "Transgene SA",
        "summary": "Transgene SA, a biotechnology company, designs, develops, and produces therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. The company's lead clinical-stage programs include TG4010, a therapeutic vaccine for the treatment of non-small cell lung cancer; Pexa-Vec, an oncolytic virus for the treatment of liver cancer; and TG4001, a therapeutic vaccine for cancers caused by the human papilloma virus. Its products in the clinical development stage also comprise TG1050, a therapeutic vaccine for the treatment of chronic hepatitis B; and TG6002, an oncolytic virus for the treatment of various solid tumors, such as glioblastoma, as well as for the cancers of the stomach, colon, pancreas, and bladder. Transgene SA has collaboration agreements with Bristol-Myers Squibb, Merck KGaA, Pfizer, and University of California Davis; licensing agreements with SillaJen, Inc. and Ascend BioPharmaceutical; agreements with Sanofi, BioInvent, Randox, and Emergent BioSolutions Inc.; collaboration and licensing agreement with Valneva; a strategic collaboration with NEC Corporation; and a collaboration with BioInvent International AB (publ) to co-develop multi-functional oncolytic viruses encoding for undisclosed antibodies sequences for treating a range of solid tumors. It also has a collaborative research and license agreement with AstraZeneca to co-develop five armed oncolytic vaccinia virus candidates. The company was founded in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.",
        "currency": "USD",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PNK",
        "market": "us_market",
        "country": "France",
        "city": "Illkirch-Graffenstaden"
    },
    "V16.F": {
        "short_name": "VIRBAC SA  EO 1,25",
        "long_name": "Virbac SA",
        "summary": "Virbac SA produces and sells medicines and vaccines for companion and food-producing animals in France and internationally. The company offers Anibidiol, a food supplement in powder/granulate form; Alizine, a contraceptive for dogs; Boviseal, a suspension to prevent intramammary infections; Bovigen Scour, a vaccine used to protect calves against viral and bacterial infections; Browse Plus, a food supplement for food producing animals; and C.E.T. Veggiedent Flex, C.E.T. Veggiedent Fr3sh, and C.E.T. Veggiedent Zen to treat bad breath in dogs. It also provides Clostrisan, a vaccine for the prevention of clostridiosis and botulism; Easotic, an auricular treatment for otitis; Effipro bovis to treat tick, flea, and louse infestations; Epiotic, an ear cleanser; Eradia to treat clostridium infections and giardiasis; Evicto, a selamectin-based endectocide treatment; Fosfosal, a trace mineral injectable supplementation; and Grofactor, a growth promoter. In addition, the company offers Hyaloral, a food supplement in tablet or gel form; Kriptazen, a halofuginone-based antiprotozoal solution; Luminal, phenobarbital-based tablet; Milpro, an internal parasiticide tablets; Moxiheart, an internal parasiticide; and Multimin, a trace element injectable supplement; Nutri-plus gel, a food supplement in oral gel form; Prevendog, deltamethrin-based parasiticides collar; Pronefra, a food supplement in case of chronic kidney disease; and Sentinel Flavor Tabs et Sentinel Spectrum, a polyvalent parasiticide tablet. Further, it provides Shotapen to treat bacterial infections; Suigen PCV2, a vaccine against porcine circovirus; Suramox, a coated amoxicillin-based antibiotic; Suprelorin, a deslorelin-based implant; Syvazul, a bluetongue vaccine; Vetemex, an antiemetic solution; Virbagest, an altrenogest-based progestin; Virbamec Platinum, an injectable solution; and Zoletil, a multi-species general anesthetic. Virbac SA was founded in 1968 and is headquartered in Carros, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers\u2014General",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "France",
        "city": "Carros"
    },
    "VETO.PA": {
        "short_name": "VETOQUINOL",
        "long_name": "Vetoquinol SA",
        "summary": "Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of pain management, anti-infective, cardiology-nephrology, care and hygiene, antiparasiticides, behavior, internal medicine, and reproduction for cats, dogs, cattle, and pigs. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers\u2014Specialty & Generic",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Lure"
    },
    "VIRP.PA": {
        "short_name": "VIRBAC",
        "long_name": "Virbac SA",
        "summary": "Virbac SA produces and sells medicines and vaccines for companion and food-producing animals in France and internationally. The company offers Anibidiol, a food supplement in powder/granulate form; Alizine, a contraceptive for dogs; Boviseal, a suspension to prevent intramammary infections; Bovigen Scour, a vaccine used to protect calves against viral and bacterial infections; Browse Plus, a food supplement for food producing animals; and C.E.T. Veggiedent Flex, C.E.T. Veggiedent Fr3sh, and C.E.T. Veggiedent Zen to treat bad breath in dogs. It also provides Clostrisan, a vaccine for the prevention of clostridiosis and botulism; Easotic, an auricular treatment for otitis; Effipro bovis to treat tick, flea, and louse infestations; Epiotic, an ear cleanser; Eradia to treat clostridium infections and giardiasis; Evicto, a selamectin-based endectocide treatment; Fosfosal, a trace mineral injectable supplementation; and Grofactor, a growth promoter. In addition, the company offers Hyaloral, a food supplement in tablet or gel form; Kriptazen, a halofuginone-based antiprotozoal solution; Luminal, phenobarbital-based tablet; Milpro, an internal parasiticide tablets; Moxiheart, an internal parasiticide; and Multimin, a trace element injectable supplement; Nutri-plus gel, a food supplement in oral gel form; Prevendog, deltamethrin-based parasiticides collar; Pronefra, a food supplement in case of chronic kidney disease; and Sentinel Flavor Tabs et Sentinel Spectrum, a polyvalent parasiticide tablet. Further, it provides Shotapen to treat bacterial infections; Suigen PCV2, a vaccine against porcine circovirus; Suramox, a coated amoxicillin-based antibiotic; Suprelorin, a deslorelin-based implant; Syvazul, a bluetongue vaccine; Vetemex, an antiemetic solution; Virbagest, an altrenogest-based progestin; Virbamec Platinum, an injectable solution; and Zoletil, a multi-species general anesthetic. Virbac SA was founded in 1968 and is headquartered in Carros, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Drug Manufacturers\u2014General",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Carros"
    },
    "VLA.PA": {
        "short_name": "VALNEVA",
        "long_name": "Valneva SE",
        "summary": "Valneva SE, a specialty vaccine company, engages in developing and commercializing vaccines for infectious diseases with unmet needs. Its portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT indicated for the prevention of Japanese encephalitis; and DUKORAL indicated for the prevention of cholera and in some countries prevention of diarrhea caused by ETEC. The company has various vaccines in development, including a vaccine against Lyme disease and single-shot vaccine against chikungunya. It has operations in Austria, Canada, France, Sweden, the United Kingdom, and the United States. The company has collaboration with Dynavax Technologies Corporation to advance vaccine development for COVID-19. Valneva SE was incorporated in 1999 and is headquartered in Nantes, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Nantes"
    },
    "VOT.SG": {
        "short_name": "VISIODENT S.A. Actions Port. EO",
        "long_name": "Visiodent S.A.",
        "summary": "Visiodent S.A. engages in the digital imaging and dental software businesses worldwide. The company offers phosphor plates scanners under the ISCAN brand name; RSV5 sensor systems; Visiocam 4 cameras; and dental imaging software under the Visiodent Imaging brand. Visiodent S.A. offers its products through distributors. The company was founded in 1982 and is based in La Plaine Saint-Denis, France. Visiodent S.A. is a subsidiary of Groupe Visiodent SAS.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "STU",
        "market": "dr_market",
        "country": "France",
        "city": "La Plaine Saint-Denis"
    },
    "VTX.PA": {
        "short_name": "VOLUNTIS",
        "long_name": "Voluntis S.A.",
        "summary": "Voluntis S.A. develops digital therapeutic solutions for diabetes, oncology, and other therapeutic areas in France and the United States. It offers Insulia, a prescription medical device that provides automated basal insulin dose recommendations and coaching messages for people with type 2 diabetes; and Diabeo, a digital solution for type 1 and type 2 patients treated on a basal-bolus insulin regimen, which suggests insulin dosage, through algorithmic calculations that are specific to the patient and based on their particular doses. The company provides Oleena, a first FDA class II software-as-a-medical device for cancer indications; AstraZeneca, an e-Cediranib Olaparib application designed for patient self-reporting and management of hypertension and diarrhea; Theraxium Oncology, a cornerstone software platform for all digital therapeutics of cancer treatment, as well as coagulation and hemophilia solutions. Voluntis S.A. has a collaboration agreement with Bristol-Myers Squibb Company to co-develop digital Therapeutics for Oncology. Voluntis S.A. was founded in 2001 and is based in Suresnes, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Health Information Services",
        "exchange": "PAR",
        "market": "fr_market",
        "country": "France",
        "city": "Suresnes"
    },
    "XUP.F": {
        "short_name": "GENFIT S.A.  EO -,25",
        "long_name": "Genfit SA",
        "summary": "Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, autoimmune, and fibrotic diseases affecting primarily the liver and gastroenterology. The company's lead products include Elafibranor, which is in pivotal Phase III clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as completed Phase II clinical trial to treat patients with primary biliary cholangitis; and Nitazoxanide that is in Phase II proof-of-concept clinical trial for the treatment of NASH-induced significant or severe fibrosis. It is also developing in-vitro diagnostic tests for the identification of patients with NASH; NIS4 for identifying patients with NASH and fibrosis; and TGFTX1 preclinical program for treating psoriasis or respiratory conditions, such as neutrophilic asthma, chronic obstructive pulmonary disease (COPD), and the asthma-COPD overlap syndrome. Genfit SA was founded in 1999 and is headquartered in Loos, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "France",
        "city": "Loos"
    },
    "XUP.SG": {
        "short_name": "Genfit S.A. Actions au Port. EO",
        "long_name": "Genfit SA",
        "summary": "Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, autoimmune, and fibrotic diseases affecting primarily the liver and gastroenterology. The company's lead products include Elafibranor, which is in pivotal Phase III clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as completed Phase II clinical trial to treat patients with primary biliary cholangitis; and Nitazoxanide that is in Phase II proof-of-concept clinical trial for the treatment of NASH-induced significant or severe fibrosis. It is also developing in-vitro diagnostic tests for the identification of patients with NASH; NIS4 for identifying patients with NASH and fibrosis; and TGFTX1 preclinical program for treating psoriasis or respiratory conditions, such as neutrophilic asthma, chronic obstructive pulmonary disease (COPD), and the asthma-COPD overlap syndrome. Genfit SA was founded in 1999 and is headquartered in Loos, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "STU",
        "market": "dr_market",
        "country": "France",
        "city": "Loos"
    },
    "XUPB.MU": {
        "short_name": "GENFIT S.A.  ADR/1 EO-,25",
        "long_name": "Genfit SA",
        "summary": "Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, autoimmune, and fibrotic diseases affecting primarily the liver and gastroenterology. The company's lead products include Elafibranor, which is in pivotal Phase III clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as completed Phase II clinical trial to treat patients with primary biliary cholangitis; and Nitazoxanide that is in Phase II proof-of-concept clinical trial for the treatment of NASH-induced significant or severe fibrosis. It is also developing in-vitro diagnostic tests for the identification of patients with NASH; NIS4 for identifying patients with NASH and fibrosis; and TGFTX1 preclinical program for treating psoriasis or respiratory conditions, such as neutrophilic asthma, chronic obstructive pulmonary disease (COPD), and the asthma-COPD overlap syndrome. Genfit SA was founded in 1999 and is headquartered in Loos, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "MUN",
        "market": "dr_market",
        "country": "France",
        "city": "Loos"
    },
    "ZVA.F": {
        "short_name": "CELLECTIS NOM.  EO-,05",
        "long_name": "Cellectis S.A.",
        "summary": "Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); ALLO-501 to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; UCART123 for the treatment of acute myeloid leukemia (AML); and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. In addition, the company produces high oleic soybean oil, other soybean products, and fiber wheat. It has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics. The company was founded in 1999 and is headquartered in Paris, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "France",
        "city": "Paris"
    },
    "ZVAA.F": {
        "short_name": "CELLECTIS SP.ADR 1 EO-,05",
        "long_name": "Cellectis S.A.",
        "summary": "Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); ALLO-501 to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; UCART123 for the treatment of acute myeloid leukemia (AML); and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. In addition, the company produces high oleic soybean oil, other soybean products, and fiber wheat. It has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics. The company was founded in 1999 and is headquartered in Paris, France.",
        "currency": "EUR",
        "sector": "Healthcare",
        "industry": "Biotechnology",
        "exchange": "FRA",
        "market": "dr_market",
        "country": "France",
        "city": "Paris"
    }
}